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 Lyme arthritis is the result of dysregulated immune response to infection by 
Borrelia burgdorferi, a tick-borne spirochete. Several immune modulators have been 
shown to be important to host defense and Lyme arthritis susceptibility, including toll-
like receptor signaling, NF-κB activation, and various cytokines and chemokines, 
including type I IFN. Here we show that type I IFN and microRNAs play critical roles in 
modulating Lyme arthritis development. 
 C3H mice exhibit an early, preclinical upregulation of type I IFN-responsive genes, 
which is associated with increased arthritis severity. Using C3H IFNAR-/- knockout mice, 
we showed that C3H mice lacking type I IFN signaling have a partial reduction in 
arthritis severity. Radiation chimeras showed that IFN signaling in both radiation 
sensitive and radiation resistant cells within the joint are required for maximal arthritis. 
Ex vivo cell sorting of cells isolated from joint tissue also showed that hematopoietic cells 
were the only cell types capable of initiating a type I IFN response after stimulation with 
B. burgdorferi, but both hematopoietic and resident cells were involved in amplification 
of the type I IFN response. Endothelial cells and fibroblasts were also major producers of 
IFN-responsive genes and inflammatory cytokines.  
 MicroRNAs have been shown to be important immune regulators, and have been 
associated with several inflammatory diseases, including rheumatoid arthritis and lupus. 
Here we show that several microRNAs were differentially expressed in B6, C3H, and B6
iv	  
 IL10-/- mice infected with B. burgdorferi. MicroRNA-146a, a repressor of TLR signaling 
and NF-κB activation, was upregulated in all three strains, suggesting it plays an 
important role in the immune response to infection. B6 miR-146a-/- mice infected with B. 
burgdorferi developed more severe arthritis, had elevated myeloid infiltration, 
upregulation of inflammatory cytokines, and had fewer numbers of bacteria in joint tissue 
at 4 weeks postinfection, indicating that miR-146a-mediated regulation of NF-κB 
activation modulated immune response and arthritis development. Similar patterns of 
dysregulation were observed in B6 miR-146a-/- macrophages, which produced excessive 
cytokines, exhibited increased phagocytosis, and had elevated protein levels of TRAF6. 
Together, these data show that miR-146a is a critical regulator of NF-κB activation and 
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Lyme Borreliosis 
 Lyme borreliosis, or Lyme disease, is an inflammatory disorder caused by infection 
of tick-borne spirochetes belonging to the genus Borrelia [1]. In Europe, most cases are 
caused by infection with Borrelia garinii and Borrelia afzelii, while Borrelia burgdorferi 
is the principal cause of Lyme borreliosis in North America [2]. The first documented 
case of infection with B. burgdorferi was in a 5,300 year-old ice mummy discovered in 
the Italian Alps [3]. Today, Lyme borreliosis is endemic to temperate regions in the 
northern hemisphere containing infected Ixodes ticks, the arthropod vector of Borrelia 
spp., which in the United States includes the Pacific north-west, upper mid-west and the 
Atlantic seaboard from Maine to Virginia [4,5]. 
 Lyme borreliosis is the most common vector-borne disease in the United States, 
with an estimated 300,000 cases per year [6]. Lyme disease was first identified because 
of an unusually high incidence of juvenile idiopathic arthritis that occurred in Lyme, 
Connecticut [7]. It was later discovered by Burgdorfer et al., that this disease was in fact 
caused by a spirochete infection transmitted through the deer tick Ixodes scapularis [1]. 
Since its identification, the geographic endemic area and number of cases has steadily 
increased [4]. This is believed to be due to a number of factors, including reforestation 
[8] and expansion of deer and host populations [9], part of which may be contributed to 
climate change [10]. 
 Lyme disease in humans occurs in three stages [2]. The first, early localized 
disease, occurs days or weeks following exposure to the pathogen and is often 
characterized by a bulls-eye rash, or erythema migrans, that spreads from the site of a tick 
bite. The second stage, early-disseminated disease, occurs weeks to months after 
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infection when spirochetes spread from the transmission site to distal sites of infection. 
Symptoms include neuropathy, facial palsy, episodes of acute arthritis, and carditis. 
Although rare, Lyme carditis has been implied as the cause of several deaths [11]. The 
third stage, late-disseminated disease, occurs months to years after infection, and may 
result in persistent or recurrent Lyme arthritis, as well as neurologic Lyme disease.  
 Lyme disease is usually resolved with effective antibiotic treatment, although 
symptoms may persist for months or years following successful treatment [12]. 
Persistence of symptoms following successful treatment remains enigmatic and several 
hypotheses have been proposed to explain this phenomenon. One is that bacterial 
antigens remain, even after antibiotic treatment [13]. Another is that the immune response 
to infection is unable to fully resolve after treatment [12]. A third is that low numbers of 
spirochetes persist, even after antibiotic treatment [14,15]. This posttreatment Lyme 
disease syndrome, sometimes called “chronic Lyme disease,” remains controversial both 
within the medical community and within the public at large [16,17]. Long-term 
antibiotic treatment of chronic Lyme disease syndrome patients continues to be 
administered by some medical professionals, despite NIH studies showing no therapeutic  
benefit over placebo controls [18]. 
 
 
Biology of Borrelia burgdorferi 
 Borrelia burgdorferi is an obligate anaerobe and, like other spirochetes, is 
characterized by their unique spiral morphology and planar wave motility, due to the 
flagella being within the periplasm [19]. B. burgdorferi is also unique in its genomic 
architecture. Its genome consists of an AT-rich 1 Mbp linear chromosome and at least 17 
linear and circular plasmids [20-22]. This genome architecture is one of the most 
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complex of all bacteria, and may play an important role in diversification of vector and 
host specificity [23], as well as virulence [24]. This genome lacks many genes essential 
for metabolism of fatty acids, amino acids, and nucleotides, nutrients which are acquired 
from their host [25]. Interestingly, B. burgdorferi is one of only a few organisms that 
does not require iron, an adaptation believed to be in response to the unavailability of 
accessible iron within their hosts and evasion of innate defense mechanisms [26]. 
 The reproductive cycle of B. burgdorferi involves transmission between their two 
hosts, ticks and small vertebrates such as mice and birds [27]. Larval and nymphal ticks 
become infected as they take a blood meal from an infected small vertebrate [5], and 
infected ticks remain infectious during molting [28]. Reservoir hosts include Paromyscus 
spp. mice, birds, and squirrels, which remain infectious until the next cycle of tick 
feeding [5]. White-tailed deer are also infected by feeding adult ticks, but are not part of 
the transmission cycle. Nevertheless, deer are important hosts for tick ecology, and 
expansion of deer populations in endemic regions is linked to the spread of Lyme disease 
[8].  
 Transmission from ticks to mammals occurs via tick salivary glands during a blood 
meal [29]. Replicating, nonmotile spirochetes remain in the mid-gut of ticks until the tick 
takes a blood meal. B. burgdorferi then become motile and move into salivary glands, 
enabling transmission to a new host [30]. As spirochetes move from tick to mammal host, 
a temperature-sensitive transcriptional change in genes encoding for surface proteins, 
among others, is required for successful transmission and continuation of the enzootic 
cycle [31,32]. Humans are incidental hosts, and are infected by both nymphal and adult 
ticks [33]. In addition to humans, domesticated animals, such as dogs and horses, are also 
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susceptible to infection and disease [34].  
 B. burgdorferi is not transmitted vertically from mother to egg; therefore it must 
persist within their hosts for many months until the next transmission cycle begins [35]. 
Borrelia contain many genes encoding for a large number of surface lipoproteins and 
adhesins, many of which are required for transmission and evasion of host immune 
response [36]. Furthermore, these bacteria are capable of varying antigenic regions of 
surface proteins through homologous recombination [37], inactivating complement [38],  




 While B. burgdorferi are able to persistently infect immunocompetent mice for at 
least a year [40], innate and adaptive immune responses are required for proper control of 
infection and spirochetemia [41,42]. Early in infection, numerous cells of the innate 
immune system are involved in host response, including endothelial cells [43], 
neutrophils [44], macrophages [45], and NK cells [46]. Toll-like receptors (TLRs) 
recognize and respond to pathogen-associated molecular patterns (PAMPs), and are 
critical for host defense, and mice lacking key TLR proteins have 10-100-fold higher 
bacterial numbers in joint, skin, and heart tissue [47-50]. The role of Toll-like receptors 
in Lyme arthritis is discussed in more detail below. Nod-like receptors are also involved 
in recognition of B. burgdorferi, although their roles in host defense are less clear 
[51,52].  
 B cell response to infection is critical in management of infections, and both T-cell-
dependent and T-cell-independent antibody production are important in host defense 
[41,53]. Nevertheless, bacterial-mediated modulation of the B cell response is believed to 
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impair antibody production and kinetics, highlighted by a lack of germinal center 
formation, which may be important for persistence [54]. Interestingly, B. burgdorferi can 
be detected inside lymph nodes, causing lymphadenopathy associated with Lyme 
borreliosis [55]. How the presence of bacteria within lymph nodes affects antibody 
production and host response is unknown, although the strong B-cell mitogenic activity  




 Lyme arthritis is one of the most common manifestations of Lyme disease, and has 
been reported in as many as 60% of untreated individuals [57]. Lyme arthritis is 
characterized by edema, synovial hyperplasia, neutrophil infiltration, and swelling, and 
arthritis severity varies among individuals, from chronic persistent arthritis to episodic 
acute arthritis to mild joint pain [57]. Arthritis is self-limiting, and is usually resolved 
upon successful antibiotic treatment [58]. In approximately 10% of cases, however, 
symptoms fail to fully resolve [58], which can develop into autoimmunity [59].  
 Manifestations of disease vary greatly amongst individuals both in terms of 
symptoms and severity, suggesting host genetic factors play a role in disease severity. 
Rheumatoid arthritis-associated HLA alleles (DRB1*0401, *0101, and *0404) have been 
linked to susceptibility to treatment-refractory Lyme arthritis [60] and production of anti-
endothelial cell growth factor (ECGF) autoantibodies [59]. Variations in abundance and 
activity of regulatory T cells have also been associated with disease severity [61]. A 
recently identified polymorphism in Toll-like receptor 1 has been linked with excessive 
cytokine and chemokine production, although the functional relevance of this 
polymorphism is unknown [62].  
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 Differences in pathogenicity and arthritis severity have also been linked to certain 
clinical isolates [63]. These isolates can either be disseminating (RST1) or non-
disseminating (RST2 and RST3) strains [64]. One group of isolates, in particular (RST1, 
OspC type A), has been linked with more severe arthritis [24]. Furthermore, individuals 
infected with this strain were more likely to develop treatment-refractory arthritis, and 
exhibited a pronounced Th1 response in synovial tissue [65]. There is evidence to suggest 
that HLA haplotype influences bacterial strain-specific susceptibility [66], although it is  
unknown how this influences infectivity and disease severity.  
 
 
Mouse Models of Lyme Disease 
 Since mice are natural hosts for B. burgdorferi, the mouse model is an excellent 
system to study disease pathogenesis. While wild strains of mice are asymptomatic upon 
infection, inbred mouse strains exhibit a spectrum of disease severity for a given 
spirochete burden, implicating genetic factors involving host response to infection 
playing an important role in pathogenesis [67,68]. For example, C57BL/6 mice develop 
mild arthritis and show little evidence of carditis, whereas C3H mice develop severe 
arthritis, despite having similar bacterial numbers in joint tissue; and have higher 
numbers of spirochetes in heart tissue and are susceptible to Lyme carditis [67].  
 Lyme arthritis in mice develops 2-4 weeks following infection with B. burgdorferi, 
and is characterized by edema, inflammatory lesions in joint tissue, remodeling of bone 
and cartilage tissue, inflammatory cell infiltration, and synovial hyperplasia [69]. These 
symptoms are also observed in human patients, who exhibit a wide range of disease 
severity, suggesting that murine Lyme arthritis faithfully recapitulates elements of human 
Lyme disease [12]. Several mouse strains are also susceptible to Lyme carditis in a strain-
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specific manner [70], but unlike humans and nonhuman primates, do not develop 
erythema migrans or neuroborreliosis [71].  
 Because the mouse model is genetically tractable, several genetic approaches have 
been used to study Lyme arthritis in mice. Forward genetics has been utilized to identify 
arthritis-susceptibility genomic loci in the murine model of Lyme arthritis [72]. Congenic 
mouse lines containing arthritis-associated quantitative trait genetic loci were developed 
which led to the discovery of a novel arthritis susceptibility gene, Gusb [73], involved in 
lysosomal degradation of complex carbohydrates. Interestingly, this Gusb polymorphism 
also influenced arthritis severity in the K/BxN serum transfer model of rheumatoid 
arthritis, suggesting that host factors influencing Lyme arthritis severity may also 
influence other inflammatory diseases. 
 Reverse genetic approaches have also been used to identify immune genes that 
impact disease severity, such as interleukin-10 [74,75] and Cxcl1 [76], as well as host 
defense, such as toll-like receptor 2 (TLR2) [48] and myeloid differentiation factor 88 
(MyD88) [47]. Other knockout studies have examined the role of dozens of immune 
genes and their role in a variety of immunological processes [77]. This approach has also 
been utilized to identify cell types that are involved in exacerbation of disease severity, 
such as neutrophils [78], and cell types that are not required for arthritis development, 
such as T and B cells [79]. 
 A third genetic approach has been used recently taking advantage of genetic screen 
tools. This enables simultaneously examining a very large number of genes in an 
unbiased manner. This approach was used to identify a previously unrecognized 
preclinical interferon profile associated with arthritis susceptibility [80]. Subsequent 
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experiments showed that dysregulation of type I interferon exacerbated disease severity 
[81]. The role of type I interferon in Lyme arthritis is discussed further below and is the 
subject of Chapter 2. A genetic screen approach was also used to identify microRNAs  
associated with Lyme arthritis severity, and is the subject of Chapter 3. 
 
 
Toll-like Receptors in Lyme Arthritis 
 Toll-like receptors recognize and respond to a number of pathogen molecular 
products, such as lipopolysaccharide, nucleic acid, and lipoproteins [82]. Recognition of 
B. burgdorferi lipoproteins by TLR2 is an important mechanism of host response to 
infection [49,83,84], and is a key element of the innate immune response [42]. TLRs 
signaling is divided into two pathways; the first dependent on the adaptor protein MyD88 
which leads to NF-κB and MAP kinase activation, and the second TRIF-dependent, 
leading to upregulation of type I interferon [82]. Signaling through TLRs leads to 
transcriptional upregulation or downregulation of thousands of genes through activation 
of several transcription factor families, including IRF3/IRF7, which upregulate type I 
interferon [85], and NF-κB family of transcription factors, which regulate many cellular 
functions, including inflammation, host defense, leukocyte function, and hematopoiesis 
[86]. 
 The importance of TLR signaling in clinical Lyme arthritis was validated in a 
recent patient study, which identified a polymorphism in TLR1 associated with a 
heightened Th1 response and increased Lyme arthritis severity [62]. TLR1/TLR2 
heterodimers have been shown to be important in B. burgdorferi recognition [87] and 
host immune response [88]. It is unknown what effect this polymorphism has on TLR 
signaling, but two hypotheses are that either it amplifies the immune response, leading to 
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elevated inflammation and arthritis, or it impairs host defense, resulting in greater  
numbers of bacteria and increased arthritis severity. 
 
 
Type I Interferon in Lyme Arthritis 
 Type I interferons (IFNs) are a family of proinflammatory cytokines important for 
host defense through activation of an antimicrobial state in a cell-intrinsic and cell-
extrinsic manner, and is critical in protection against viral pathogens [89]. Dysregulation 
of type I IFNs are also associated with increased disease severity. In certain bacterial 
infections, induction of type I IFN can lead to impaired host defense, in part through 
suppression of pathways important for bactericidal function, including IFN-γ signaling 
[90]. In addition, type I IFN-based therapy is associated with development of 
autoimmunity [91]. A hallmark feature of systemic lupus erythematosus (SLE) is 
constitutive type I IFN production by plasmacytoid dendritic cells, leading to immune 
activation and autoantibody production [92].  
 As mentioned earlier, the role of type I IFN in Lyme arthritis development was first 
identified through microarray expression analysis [80]. Subsequent research by Miller et 
al. showed that abrogation of this IFN signature at 1 week postinfection led to a partial 
decrease in Lyme arthritis severity at 4 weeks postinfection [81]. TLRs, especially those 
that recognize nucleic acids, are important activators of type I IFN [82], and B. 
burgdorferi RNA has been shown to initiate a type I IFN response [93]. TLR2, 
traditionally associated with MyD88-dependent signaling, is also able to activate type I 
IFN upon B. burgdorferi stimulation in a TRIF-dependent manner [94]. In addition to 
TLRs, NOD2, an intracellular pattern recognition receptor, is also capable of inducing a 
type I IFN signature in response to B. burgdorferi [95]. Further elucidation into joint cell 
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types associated with induction and amplification of the arthritogenic type I IFN response  
is the subject of Chapter 2. 
 
 
NF-κB Activation in Lyme Arthritis 
 Infection with B. burgdorferi leads to TLR-mediated NF-κB activation [43], and 
has been shown to play a critical role in host defense during B. burgdorferi infection, 
since mice lacking CD14, TLR2, or the adapter protein MyD88 are unable to control 
infection [48,96,97]. Not surprisingly, these mice also develop severe arthritis, probably 
due to the very high bacterial burden in joint tissue.  
 While NF-κB activation is essential in controlling infection, downregulation and 
return to homeostasis is also important in order to prevent persistent inflammation, tissue 
damage, and autoimmunity [98]. Failure to downregulate NF-κB-activated cytokines can 
lead to increased Lyme arthritis severity and development of treatment-refractory arthritis 
[62,99]. This failure to down-modulate NF-κB is also observed in synovial cells and 
peripheral blood mononuclear cells from patients with other inflammatory disorders, such 
as rheumatoid arthritis and lupus [100]. While evidence suggests that proper regulation of 
TLR/NF-κB signaling is important in limiting Lyme arthritis development in both mice 
and humans, decoupling its role in host defense from arthritis development has remained 
difficult. 
 Many CXC chemokines are regulated by NF-κB, and influence inflammation and 
host defense through recruitment of neutrophils (CXCL1, CXCL2), T cells (CXCL9, 
CXCL10), and B cells (CXCL12, CXCL13) [101]. Neutrophil chemokines, particularly 
CXCL1, are important for arthritis development [76]. CXCL1 is tightly regulated at the 
transcriptional and posttranscriptional level [102]; TLR, IL-1, or TNFα stimulation 
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results in Cxcl1 upregulation, which is dependent on two NF-κB binding sites [103], and 
is further regulated by the presence of multiple 3’ UTR AU-rich elements [104]. 
 In addition to arthritis, TLR signaling also plays an important role in 
neuroborreliosis in humans and nonhuman primates [105]. In humans, elevated levels of 
IL-6 and CXCL13 in serum and cerebral spinal fluid correlate with active 
neuroborreliosis [106], and elevated levels of IL-6 and IL-1β are speculated to be 
associated with neuropsychiatric symptoms observed in some patients [107]. 
Furthermore, failure to upregulate TNFα in nervous tissue early in infection is correlated 
with development of chronic Lyme neuroborreliosis, suggesting that this cytokine is 
important for early elimination of bacteria [108]. Although mice do not develop 
neuroborreliosis, studying the role of TLR/NF-κB signaling in murine Lyme arthritis may 
shed light on mechanisms of other clinical manifestations of Lyme disease. Because of 
the central role of TLR signaling in host defense and disease pathogenesis, understanding  
TLR regulation is critical in elucidating mechanisms of arthritis and inflammation. 
 
 
MicroRNAs in TLR Signaling and Autoimmunity 
 MicroRNAs are small, noncoding regulators of translation [109]. Since their 
discovery, microRNAs have been shown to play important roles in many biological 
processes, including immune response and inflammation and autoimmunity [110,111]. 
MicroRNAs act as translational inhibitors by recognizing and binding to 3’ UTR of target 
mRNAs [112]. Over 1,000 microRNAs have been identified in humans and mice, and 
many microRNAs are capable of targeting many different genes [109]. Because of this, it 
is believed that as many protein-coding genes are regulated by microRNAs [113,114]. 
 A number of microRNAs are upregulated by TLR/NF-κB activation, including the 
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anti-inflammatory microRNA miR-146a and the proinflammatory microRNA miR-155 
[115]. These microRNAs are important in providing feedback regulation of NF-κB 
signaling, and are required for maintaining immune homeostasis [115]. Because NF-κB is 
a key node in many cellular responses, these microRNAs have been shown to modulate a 
number of inflammatory responses [116]. 
 Several microRNAs are differentially expressed in rheumatoid arthritis (RA) 
synovial tissue, including miR-146a and miR-155 [117,118]. Overexpression of miR-
146a in RA patients is highly correlated with elevated levels of the arthritogenic cytokine 
TNFα and disease severity [119,120], although it is not known whether this is a marker of 
sustained inflammation or points to functional inability of miR-146a to modulate the 
inflammatory response. In support of the latter, a polymorphism in the 3’-UTR of 
IRAK1, a target of miR-146a [121], was identified to be positively associated with RA 
susceptibility. In a mouse study, addition of exogenous miR-146a was able to partially 
reduce pathology in the mouse collagen induced arthritis model [122]. Mouse studies 
have also shown that absence of miR-155 was able to reduce arthritis severity in both 
collagen-induced arthritis and K/BxN serum transfer arthritis, two models for RA [123]. 
Similarly, microRNA-182 was shown to be an important regulator of T cell clonal 
expansion in the ovalbumin-induced model of RA [124].  
 MicroRNAs miR-146a and miR-155 have also been associated with systemic lupus 
erythematosus (SLE) [125,126]. Unlike in RA, there appears to be an inverse relationship 
between miR-146a expression and the type I IFN signature, a marker for increased 
disease severity [127]. Furthermore, polymorphisms within the promoter region of miR-
146a are associated with susceptibility to SLE [128,129]. In mice, several microRNAs, 
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including miR-155, share similar expression patterns in different lupus models [130]. 
 MicroRNAs are also required for regulation of other inflammatory and autoimmune 
diseases [131]. For example, miR-155 expression is an important component of 
experimental autoimmune encephalitis (EAE), a mouse model for multiple sclerosis 
[132], through miR-155-dependent regulation of Th17 cell activation [133]. Conversely, 
microRNA-124 is a suppressor of EAE severity through its function in macrophages 
[134]. In the NOD mouse model of type 1 diabetes, miR-21, another TLR-induced 
microRNA, is an important modulator of pancreatic beta cell death through suppression 
of the proapoptotic gene Pdcd4 [135]. 
 The studies and findings, both in humans and in mouse models, strongly support 
the notion that microRNAs are important regulators of inflammation and autoimmunity. 
However, no studies have been done examining the role of microRNAs in regulating 
Lyme arthritis. Chapter 3 of this dissertation examines microRNA expression in Lyme  
arthritis and discusses how miR-146a modulates arthritis severity. 
 
 
Preview of Thesis Research 
 The focus of this dissertation is examining the roles of type I interferon and 
microRNAs in modulating Lyme arthritis severity. Chapter 2 builds on previous studies 
by Crandall et al. and Miller et al., showing the importance of type I interferon in arthritis 
development in the C3H mouse model of Lyme disease [80,81]. This study focuses on 
cellular sources of arthritogenic type I interferon response, as well as cell types involved 
in initiation of this response.  
 Chapter 3 contains the results of a study researching the role of microRNAs in 
Lyme arthritis development. This study focuses on one microRNA, miR-146a, and its 
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critical role as a suppressor of inflammation and arthritis. MicroRNA-146a was identified 
in a microRNA microarray screen as being highly induced during infection with B. 
burgdorferi. 
 Included in Appendix A are data from another microRNA identified in the 
microarray, miR-155. This microRNA was uniquely upregulated in the B6 IL10-/- mouse 
model of Lyme arthritis, and its upregulation is consistent with a previous report showing 
that IL-10 is a negative regulator of miR-155 [136]. Also included (Appendix B) are 
results on the role of IL-10 in regulating persistent Lyme arthritis development and T cell 
activation, an extension of previous work performed by Sonderegger et al. [75]. 
Appendix C includes results showing that miR-146a also influences the K/BxN serum  
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Endothelial Cells and Fibroblasts Amplify the Arthritogenic
Type I IFN Response in Murine Lyme Disease and Are Major
Sources of Chemokines in Borrelia burgdorferi-Infected Joint
Tissue
Robert B. Lochhead,*,1 F. Lynn Sonderegger,*,1 Ying Ma,*,1 James E. Brewster,*
Doug Cornwall,* Heather Maylor-Hagen,* Jennifer C. Miller,*,2 James F. Zachary,†
John H. Weis,* and Janis J. Weis*
Localized elevation in type I IFN has been uniquely linked to the severe Lyme arthritis that develops in C3H mice infected with the
spirochete Borrelia burgdorferi. In this study, the dynamic interactions that result in generation of these responses were further
examined in C3H mice carrying the type I IFN receptor gene ablation, which effectively blocks all autocrine/paracrine signaling
crucial to induction of downstream effectors. Reciprocal radiation chimeras between C3H and IFNAR12/2 mice implicated both
radiation-sensitive and radiation-resistant cells of the joint tissue in the proarthritic induction of type I IFN. Ex vivo analysis of
cells from the naive joint revealed CD45+ cells residing in the tissue to be uniquely capable of initiating the type I IFN response to
B. burgdorferi. Type I IFN responses were analyzed in real time by lineage sorting of cells from infected joint tissue. This
demonstrated that myeloid cells, endothelial cells, and fibroblasts were responsible for propagating the robust IFN response,
which peaked at day 7 postinfection and rapidly resolved. Endothelial cells and fibroblasts were the dominant sources of IFN
signature transcripts in the joint tissue. Fibroblasts were also the major early source of chemokines associated with polymor-
phonuclear leukocyte and monocyte/macrophage infiltration, thus providing a focal point for arthritis development. These find-
ings suggest joint-localized interactions among related and unrelated stromal, endothelial, and myeloid cell lineages that may be
broadly applicable to understanding the pathogeneses of diseases associated with type I IFN signature, including systemic lupus
erythematosus and some rheumatoid arthritides. The Journal of Immunology, 2012, 189: 2488–2501.
L yme disease in humans is caused by infection with the tick-borne spirocheteBorrelia burgdorferi and results in clinicalarthritis in up to 30% of infected individuals (1, 2). Lyme
arthritis has been extensively studied in the C3H mouse, which
replicates many of the features of acute human disease, including
edema, synovial hyperplasia, inflammatory cell infiltration, and
reactive/reparative changes associated with joint tissue (3). A range
of arthritis severity has been observed in humans and in different
inbred strains of mice, as initially reported by Steere and Barthold
et al. (2, 4). Additionally, numerous studies in mice have suggested
that characteristics of the B. burgdorferi-induced inflammatory
cascade determine the severity of arthritis that develops (5, 6). For
example, ablation of the anti-inflammatory gene IL-102/2 results
in greater severity of Lyme arthritis in both B6 and C3Hmice (7, 8).
Previous global gene expression analysis in the joint tissue of
C3H mice revealed an early inflammatory response at 1 wk of
infection, weeks prior to the development of arthritic lesions (9).
This early transcriptional event was characterized by robust but
transient induction of IFN-responsive transcripts, and was absent
from the mildly arthritic B6 mice. Innate immune production of
type I IFNs (IFN-a,b) was suspected, as type II IFN (IFN-g) is not
required for Lyme arthritis development in C3H mice (10). Ad-
ditionally, the peak of IFN-inducible transcript induction was prior
to infiltration of lymphocytes into joint tissue likely to be required
for IFN-g production (11, 12). The involvement of type I IFN in
Lyme arthritis was subsequently confirmed through the systemic
administration of a type I IFN receptor (IFNAR1)-blocking mAb
that was capable of disrupting signaling by all type I IFNs. This
treatment suppressed the spike in IFN-inducible transcripts in the
joint tissue at 1 wk of infection and the subsequent development of
arthritis at 4 wk postinfection (13). In contrast, blocking IFN-g
suppressed expression of many of the overlapping IFN-inducible
transcripts, but did not result in reduced arthritis severity.
The unique contribution of type I IFN to the development of
severe Lyme arthritis in C3H mice implies specialized targets for
this IFN in the infected joint tissue that cannot be compensated with
IFN-g. The potential importance of this finding is underscored by
the pathological role of type I IFNs in systemic lupus eryth-
ematosus (SLE) and in the injurious side effects associated with
IFN-ab–based therapies for multiple sclerosis and hepatitis C
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infection (14–16). Even more relevant to Lyme arthritis patho-
genesis are recent studies implicating type I IFN in a subgroup of
rheumatoid arthritis (RA) patients who fail to respond to thera-
peutic TNF blockade (17–19). Thus, studies with Lyme arthritis
may broadly improve our understanding of immune-mediated
inflammatory diseases by providing insight for patient groups
currently not well served by existing therapies.
To further our understanding of the contribution of type I IFN
signaling in thedevelopmentofLymearthritis, the IFNreceptor1gene
ablation (IFNAR12/2) was crossed onto the C3H background (C3H
IFNAR12/2). Arthritis severity was reduced in the absence of
IFNAR1. The development of radiation chimeras between C3H and
IFNAR12/2 mice allowed assessment of contributions of both my-
eloid lineage and parenchymal cells to the proarthritic IFN response:
both developmental lineages were involved. Ex vivo recovery of
sorted cells from the joint tissue revealed dynamic contributions of
various cell lineages to the arthritis-promoting IFN response. Resi-
dent myeloid cells of the joint tissue were identified as the initiators
of type I IFN production upon encounter with B. burgdorferi,
whereas endothelial cells and joint fibroblasts expressing adhesion/
activation markers were found to amplify the response and served
as the major source of disease-promoting chemokines. The devel-
opment of severe arthritis was determined to be orchestrated by
a cascade of events initiated by interaction of B. burgdorferi with
myeloid, stromal, and endothelial cells at 1 wk postinfection.
Materials and Methods
Mice, bacterial cultures and infections, and assessment of
arthritis severity
C3H/HeN mice were obtained from Charles River Breeding Laboratories or
from National Cancer Institute, and C57BL/6 mice were from National
Cancer Institute. The IFNAR1 gene ablation from the C57BL/6 mouse (20)
(provided by M.-K. Kaja, University of Washington, Seattle, WA) was
crossed six generations onto the C3H background. Filial mating was per-
formed to generate C3H/HeN IFNAR12/2. All mice were housed in the
University of Utah Animal Research Center (Salt Lake City, UT) following
all institutional guidelines for the care and use of mice in biomedical re-
search. Mice were infected with 2 3 104 bacteria of the clonal B. burg-
dorferi strain N40 by intradermal injection into the skin of the back (3).
Infected and control C57BL/6 mice received 5 3 104 U universal type I
IFN (PBL) on day 1 and 104 U every other day for 28 d by i.p. injection, or
received an equivalent volume of PBS (21). Ankle measurements were
obtained using a metric caliper before and at 4 wk of infection. Rear ankle
joints were prepared for assessment of histopathology by removal of skin
and fixation of the tissue in 10% neutral buffered formalin, as described
(8). Decalcified joints were embedded in paraffin, sectioned at 3 mm, and
stained with H&E. Each slide was scored from 1 to 5 for various aspects of
disease, including severity and extent of the lesion, polymorphonuclear
leukocyte (PMN) and mononuclear cell (e.g., monocytes, macrophages)
infiltration, tendon sheath thickening (e.g., synoviocyte and fibroblast
hyperplasia), and reactive/reparative responses (e.g., periosteal hyperplasia
and new bone formation and remodeling), with 5 representing the most
severe lesion, and 0 representing no lesion. Ankle measurements and ar-
thritic lesions were assessed in coded samples. Infection was confirmed in
mice euthanized prior to 14 d postinfection by culturing bladder tissue in
BSK II media containing 6% rabbit serum, phosphomycin, and rifampicin.
ELISA quantification of B. burgdorferi-specific IgM and IgG concen-
trations was used to confirm infection in mice euthanized at and after
14 d postinfection, as described (22).
Preparation of single-cell suspensions from mouse tissue
Single-cell suspensions were prepared from the rear ankle joint tissue,
following removal of skin. Joint tissue was partially removed from bone
using 20-gauge syringe needles to facilitate digestion by incubation in
RPMI 1640 containing 0.2 mg/ml endotoxin-free Liberase TM (Roche) and
100 mg/ml DNase I (Sigma-Aldrich) for 1 h at 37˚C. After incubation,
gentle pipetting further disrupted tissue and intact tissue was broken apart
using the end of a 5-ml syringe. The single-cell suspension was filtered
through a 100 mm cell strainer and centrifuged, and the RBCs were lysed
using ammonium-chloride-potassium lysing buffer. Blood was collected in
Eppendorf tubes containing acid citrate dextrose, and leukocyte pop-
ulations were analyzed, as described (23).
Flow cytometry
All flow cytometry data were analyzed using BD CellQuest Pro software.
Sorting experiments were performed using a BD FACSAria II. All other
FACS data were collected on a BD FACS Canto II flow cytometer or BD
LSRII flow cytometer. The 7-aminoactinomycin D (eBioscience) or DAPI
(Invitrogen) was used in all experiments, and dead cells were excluded from
analyses, as were doublet cells. All Abs used for flow cytometry were
purchased from either BioLegend or eBioscience. Unconjugated Fc blocking
Ab (clone 93; BioLegend) was included in all Ab-labeling experiments.
Position of gates for sorting and analysis was based on analysis of appro-
priate isotype controls. Fluorochrome-conjugated Abs and isotype controls
used in this study were as follows: FITC-conjugated anti-CD11b (M1/70)
and anti-B220 (RA3-6B2); PerCP/Cy5.5-conjugated anti-Ly6c (HK1.4) and
anti-CD31 (390); PE-conjugated anti-CD54 (YN1/1.7.4), anti-CD31 (390),
anti-IFNAR1 (MAR1-583), and anti-CD29 (HMb1-1); PE/Cy-7–conju-
gated anti-CD11b (M1/70), anti-CD90.2 (30-H12), and anti-CD45.2 (104);
allophycocyanin-conjugated anti-F4/80 (BM8), anti-TCR b (H57-597),
anti-CD29 (HMb1-1), anti-CD45 (30-F11), and anti-CD106 (429);
Alexa Fluor 700-conjugated anti-Ly6G/Ly6C (RB6-8C5) and anti-CD45.2
(104); Pacific Blue-conjugated anti-TCRb (H57-597) and anti-B220 (RA3-
6B2); and biotin-conjugated anti-PE (PE001) and PE-conjugated strepta-
vidin.
Injection of mAbs
The followingAbs were used in vivo for cytokine neutralization: anti–IFN-g
(XMG1.2), anti–TNF-a (XT3.11), and rat IgG1 (HPRN) isotype control,
and were aggregate, endotoxin free, and sterile (Bio X Cell). Groups of five
to six mice received 1 mg indicated Ab 1 d prior to infection, followed by
0.5 mg of the same Ab every 4–5 d thereafter, all by i.p. injection (11, 13).
Isolation of RNA and quantitative RT-PCR
For all experiments examining gene expression in joint tissue, mice were
killed, and the skin was removed from the tibiotarsal joints. Ankle joints
were excised, frozen immediately in dry ice/ethanol, and stored at 280˚C.
Total RNA from joint tissue and cultured cells was performed using
TRIzol reagent (Invitrogen) (24). RNA from FACS-sorted cell populations
was purified with the RNAeasy kit (Qiagen). RNA recovered from tissue
and cells was reverse transcribed, and transcripts were quantified using a
Roche LC-480 according to our previously described protocols (24).
Primer sequences used in this study were as follows: Ccl2 forward (59-
CCCAATGAGTAGGCTGGAGAGC-39), reverse (59-GGTGGTTGTGG-
AAAAGGTAGTGG-39); Ccl8 forward (59-GCTTCTTTGCCTGCTG-
CTCATAG-39), reverse (59-CATCTGCTTGTAACATCTCTCTGCC-39);
Cxcl1 forward (59-ATGGCTGGGATTCACCTC-39), reverse (59-CTTCA-
GGGTCAAGGCAAG-39); Cxcl2 forward (59-CCCACTGCGCCCAGA-
CAG-39), reverse (59-AGGTCAGTTAGCCTTGCCTT-39); Fn1 forward
(59-GCAGTGGTCATTTCAGATGCG-39), reverse (59-TCTCCCTTTCC-
ATTCCCGAG-39); Icam1 (CD54) forward (59-AGGGCTGGCATTGT-
TCTCTA-39), reverse (59-CTTCAGAGGCAGGAAACAGG-39); Pecam1
(CD31) forward (59-TCCTTCACCATCAACAGCATCC-39), reverse (59-
TTTTGTCCAGTGTCACCTTGGG-39); Ptprc (CD45) forward (59-GGG-
TCCACCTACATAAATGCCAG-39), reverse (59-GTTCCTGTTTCCTTC-
TTCACATCG-39); Thy1 (CD90) forward (59-GGATGAGGGCGAC-
TACTTTTGTG-39), reverse (59-TTCTGAACCAGCAGGCTTATGC-39);
Vcam1 (CD106) forward (59-CCCGTCATTGAGGATATTGG-39), reverse
(59-GGTCATTGTCACAGCACCAC-39). Primer sequences for b-actin,
Igtp, Iigp, Mmp3, Stat1, Cxcl13 (9), Cxcl9, Cxcl10, Oasl2 (13), Ifit, Gbp2
(25), Tnfa, and Ifnb (26) can be found in the indicated citations.
Isolation of DNA and quantification of joint spirochetes
For quantification of joint spirochetes at 4 wk postinfection, total DNAwas
isolated from joint tissue, as described. PCR quantification of spirochetes
was performed by amplification of the B. burgdorferi recA gene and
normalized to the mouse Nidogen gene using a Roche LC-480 (27).
Generation of reciprocal radiation chimeras
The diminished severity of Lyme arthritis in mice 10 wk and older required
the development of a protocol allowing rapid reconstitution of irradiated
mice with high numbers of hematopoietic cells (11). C3H and C3H
IFNAR12/2 mice 5 wk of age were lethally irradiated with 2 doses of 525
cGy 3 h apart using a GE Isovolt Titan. Twenty-four hours following ir-
radiation, splenocytes were harvested from C3H or C3H IFNAR12/2 do-
nor mice, and 2 3 107 splenocytes in a 200 ml volume were injected i.v.
The Journal of Immunology 2489




into each irradiated recipient. Chimerism was determined at 6 wk postir-
radiation by flow cytometry assessment of mAb anti-IFNAR1 expression
by blood leukocytes (28). Staining required sequential treatment with PE-
conjugated anti-IFNAR1, biotin-conjugated anti-PE, and PE-conjugated
streptavidin, which allowed sufficient fluorescence intensity to readily
distinguish wild-type from IFNAR12/2 cells. Peripheral blood B cells and
monocytes were found to be .90% donor derived, whereas T cells were
∼60% donor derived. Total blood leukocyte counts were comparable to
those from nonirradiated control mice 7 wk posttransplantation. Mice were
infected at 3 wk postirradiation and transplantation, 7–8 wk of age and,
therefore, allowing Lyme arthritis to be assessed.
Cell culture
Bone marrow-derived macrophages (BMDM) were isolated from the fe-
murs and tibias of mice, as previously described (29). Macrophage cultures
were plated in 12-well dishes at a density of 6 3 105/ml in media con-
taining the serum replacement Nutridoma (Roche) and stimulated with live
B. burgdorferi cN40 (7.4 3 106/ml), 10 U/ml IFN-g (Sigma-Aldrich), or
PBS. Macrophage cultures were stimulated at 37˚C, 5% CO2, and har-
vested either at 6 h for RNA extraction or at 24 h for assessment of type I
IFN in supernatants by bioassay.
Magnetic separation of leukocytes and stromal cells from naive
joint tissue
Single-cell suspensions of joint tissue were labeled with biotinylated anti-
CD45.2 (BioLegend), followed by labeling with streptavidin magnetic
beads (Miltenyi Biotec). Labeled cells were loaded onto MS columns
(Miltenyi Biotec), and magnetic separation was performed according to the
manufacturer’s instructions, with sequential application to a second col-
umn. Relative purity of the CD45.2+ and CD45.22 populations was de-
termined by flow cytometry using allophycocyanin-conjugated anti-CD45
(clone 30-F11), which recognizes an epitope distinct from the Ab used in
magnetic bead sorting (anti-CD45.2, clone 104). Unfractionated and
fractionated populations were incubated in 2% FBS containing RPMI 1640
in the presence or absence of B. burgdorferi, 100 U mouse rIFN-b (PBL),
or both for 6 h, conditions found to maintain cell viability and permit IFN-
inducible responses to be detected. Samples were collected in TRIzol for
RNA recovery (24).
Type I IFN bioassay
Bioactive type I IFN was detected in culture supernatants from BMDM
incubated for 24 h with B. burgdorferi in the presence or absence of rIFN-g
(eBioscience) by bioassay with B16-Blue IFN-ab cells (InvivoGen), fol-
lowing manufacturer’s directions. Standard curve was generated with
mouse rIFN-b (PBL).
Data and statistical analyses
All graphical data represent the mean 6 SEM. Statistical analysis was
performed using Prism 5.0c software. Multiple-sample data sets were
analyzed by one-way ANOVA with appropriate post hoc test for pairwise
comparisons (Figs. 2–6, Tables II, III). Two-sample data sets were ana-
lyzed by Student t test (Figs. 1, 8, Table I). Categorical data for histopa-
thology was assessed by the Mann–Whitney U test (Figs. 1, 3, Table I).
Statistical significance (p , 0.05) is indicated by *.
Results
Lyme arthritis severity can be modulated by augmentation or
ablation of type I IFN signaling
We previously demonstrated that administration of a blocking mAb
to the type I IFN receptor resulted in a significant diminution of
arthritis severity in B. burgdorferi-infected C3H mice, implicating
the type I IFN autocrine/paracrine pathway in arthritis develop-
ment (13). As this pathway is not upregulated in the joint tissue of
arthritis-resistant B6 mice, we tested the effect of supplementation
of B. burgdorferi-infected B6 mice with type I IFN throughout B.
burgdorferi infection. Treatment of B6 mice with daily injections
of IFN-a for 4 wk following infection resulted in significantly
greater ankle swelling than observed in the control group, receiv-
ing daily injections of PBS (Table I). Histopathologically assessed
lesion scores suggested a trend toward increased arthritis in the
group receiving IFN-a; however, this did not achieve statistical
significance. Importantly, the increase in ankle swelling in treated
B6 mice (Table I) did not reach the degree of severe arthritis seen
in the genetically susceptible C3H mice (Fig. 1). This finding may
further indicate the presence of IFN regulatory mechanisms in-
herent to the B6, but not the C3H genetic background.
As the previous assessment of type I IFN in Lyme arthritis was
performed in vivo using a mAb to prevent signaling though the
cognate receptor, a more rigorous approach was used by crossing
the IFNAR1 gene disruption onto the susceptible C3H genetic
background. Marker-assisted protocols were employed for rapid
and complete crossing and to ensure that none of the quantitative
trait loci associated with Lyme arthritis severity were lost from the
recipient C3H mice (30). Infection of C3H IFNAR12/2 mice with
B. burgdorferi revealed a significant reduction in arthritis severity
relative to wild-type C3H mice, as demonstrated by the traits of
ankle swelling, overall lesion score, and neutrophil infiltration
(Fig. 1), with less robust differences in tendon sheath thickness and
reactive/reparative abnormalities also observed (data not shown).
These results mirror the significant but incomplete reduction in
arthritis severity previously reported in C3H mice treated with
IFNAR receptor-blocking Ab prior to infection, thus indicating
that the observed partial reduction in arthritis was not reflective of
incomplete neutralization by the Ab (13). Three lines of experi-
mental evidence now support the unique involvement of type I
IFN in arthritis development in C3H mice, as follows: 1) arthritis
can be partially suppressed with receptor-blocking mAb; 2) ar-
thritis is similarly reduced by genetic ablation of the IFN signaling
pathway; and 3) ankle swelling can be partially restored in B6
mice by administration of exogenous IFN-a. A modest increase in
B. burgdorferi levels in joint tissue of IFNAR12/2 mice was ob-
served, and demonstrated that the decreased arthritis seen in the
mutant mice was not secondary to reduced numbers of spirochetes
in the tissue (Fig. 1).
Effect of type I IFN receptor ablation on
B. burgdorferi-induced IFN profile in joint tissue and in
macrophage cultures
The contribution of type I IFN signaling to the previously reported
robust upregulation of IFN-responsive transcripts was assessed in
C3H IFNAR12/2 mice at 1 wk of B. burgdorferi infection. In-
terestingly, several of the IFN-inducible transcripts previously
found to be reduced but not eliminated by receptor-blocking mAb
also displayed residual induction in the joint tissue of B. burg-
Table I. Effect of IFN-a administration on arthritis development in B. burgdorferi-infected B6 mice
Infection Status IFN Treatment Change in Ankle Measurementa Overall Lesion
Mock infected PBS 0.01 6 0.01a 0 6 0
B. burgdorferi 0.04 6 0.04 1.0 6 0.71
Mock infected IFN-a 0 6 0 0 6 0
B. burgdorferi 0.25* 6 0.15 1.6 6 0.55
Assessed at 4 wk of infection.
aValues represent mean 6 SD.
*Statistical significance between PBS- and IFN-a–treated group, p , 0.05.
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dorferi-infected C3H IFNAR12/2 mice, shown for Cxcl10, Oasl2,
Igtp, and Gbp2 in Fig. 2A, although at much lower levels than
previously reported in wild-type C3H mice (9, 13, 24).
Recent reports in other infection models have identified modi-
fying effects of type I IFN on IFN-g production (31, 32) as well as
MyD88-dependent modulation of IFN-b production (33). The
identification of low levels of transcripts for both IFN-g and
TNF-a in the joint tissue of infected C3H IFNAR12/2 mice (data
not shown) suggested that one or both might be responsible for
induction of the IFN profile in absence of type I IFN signaling.
Injecting infected C3H IFNAR12/2 mice with neutralizing Abs
for IFN-g or TNF-a allowed testing of this possibility. Treatment
with anti-TNF resulted in detectable, but not significant, reduction
in the expression of several IFN-inducible transcripts in infected
joint tissue when compared with mice treated with an isotype
control mAb (Fig. 2A). In contrast, treatment with IFN-g neu-
tralizing mAb resulted in complete suppression of the expression
of IFN-inducible genes to levels found in uninfected mice (Fig.
2A). Thus, the residual profile of IFN-inducible transcripts in
infected IFNAR12/2mice can be attributed to compensatory effects
of IFN-g, possibly reflecting an enhanced effect permitted by the
absence of type I IFN modulatory activity.
IFN-g partially compensates for type I IFN signaling ablation
in the BMDM response to B. burgdorferi, but does not
substitute for type I IFN in arthritis development
The B. burgdorferi-induced upregulation of IFN-inducible tran-
scripts in BMDM was previously shown to be dependent on IFN
receptor-mediated autocrine/paracrine signaling in B6 mice (13).
BMDM were prepared from C3H and C3H IFNAR12/2 mice, and
the presence of the receptor was again shown to be necessary for
upregulation of IFN-inducible transcripts in response to B. burg-
dorferi, shown for Cxcl10, Oasl2, Igtp, and Gbp2 (Fig. 2B). Im-
portantly, C3H IFNAR12/2 BMDM were able to respond to B.
burgdorferi by other sensing/signaling pathways, as indicated by
upregulation of Tnfa transcripts at concentrations similar to C3H
BMDM (Fig. 2C).
The mAb results in Fig. 2A suggested that IFN-g might com-
pensate for type I IFN signaling in induction of the IFN tran-
scriptional response to B. burgdorferi. To model the potential of
IFN-g to compensate for type I IFN within the joint, exogenous
IFN-g was added to BMDM cultures of C3H and C3H IFNAR12/2
macrophages stimulated with B. burgdorferi (Fig. 2B). Treat-
ment with rIFN-g alone resulted in the induction of most tran-
scripts in both wild-type and IFNAR12/2 macrophages, but with
a range of expression, shown for Cxcl10, Oasl2, Igtp, and Gbp2.
Costimulation with IFN-g and B. burgdorferi resulted in expression
of IFN-inducible transcripts in both C3H and C3H IFNAR12/2
macrophages, shown for Cxcl10, Igtp, and Gbp2 in Fig. 2B.
However, expression of Oasl2, a transcript linked to early type I
IFN responses, was not upregulated in C3H IFNAR12/2 macro-
phages costimulated with IFN-g and B. burgdorferi. The reduced
expression of Igtp and Gbp2 when stimulated simultaneously with
IFN-g and B. burgdorferi may reflect a rapid response to dual
stimuli that was missed by the 6-h time point (Fig. 2B).
Interestingly, transcriptional induction of IFN-b was observed
at low concentrations in response to B. burgdorferi in both wild-
type and IFNAR12/2 macrophages and was further upregulated
by the addition of IFN-g (Fig. 2C). The induction of IFN-b
transcripts in C3H IFNAR12/2 macrophages defines this early
production (6 h) as independent of positive feedback through type
I IFN receptors. To ensure that these transcripts reflected the
translation and release of type I IFN protein (IFN-a and IFN-b),
macrophage supernatants collected at 24 h were subjected to
bioassay for type I IFN using the B16-Blue cell line (InvivoGen)
(Fig. 2C). Type I IFN secretion was detected in C3H BMDM
stimulated with B. burgdorferi, whereas IFN-g alone did not have
this effect. Treatment with IFN-g enhanced production of type I
IFN protein in responses to B. burgdorferi, in macrophages from
both C3H and C3H IFNAR12/2 mice. Of note, bioassay results
were confirmed to be specific for type I IFN as these findings were
not influenced by the addition of neutralizing Ab to IFN-g (data
not shown).
The observation that the residual IFN profile seen in infected
C3H IFNAR12/2 was suppressed by anti–IFN-g neutralizing mAb
(Fig. 2A) clearly implicates IFN-g in the localized response to B.
burgdorferi in the joint of C3H IFNAR12/2 mice, and suggests it
could contribute to the residual arthritis seen in these mice. To
test this hypothesis, groups of five infected C3H IFNAR12/2 mice
were administered IFN-g neutralizing mAb or isotype control
mAb by i.p. injection every 5 d for 4 wk. IFN-g neutralization did
not cause further reduction in the severity of arthritis in C3H
IFNAR12/2 mice: average ankle swelling for five mice treated
with isotype control was 0.80 6 0.23 mm, whereas mice treated
with anti–IFN-g measured 0.803 6 0.17 mm. This finding indi-
cates that the IFN-g–dependent induction of transcripts in the joint
tissue of infected IFNAR12/2 mice at 1 wk postinfection does not
contribute to the residual arthritis seen at 4 wk postinfection,
consistent with our previous published results employing blocking
mAbs in C3H mice (13). Therefore, the residual arthritis seen in B.
burgdorferi-infected C3H IFNAR12/2 mice develops indepen-
dently of either type I or type II IFN.
FIGURE 1. IFNAR1 gene ablation results in re-
duced Lyme arthritis severity in C3H mice. C3H or
C3H-IFNAR12/2 mice were infected with B. burg-
dorferi by intradermal injection, and arthritis was
assessed at 4 wk, as described in Materials and
Methods. Arthritis traits included the following: change
in ankle joint measurement, PMN infiltration, and
overall lesion severity. B. burgdorferi number in joint
tissue was determined by quantitative PCR and nor-
malized to the single copy mouse gene Nidogen. Sta-
tistical significance was determined by Student t test
for ankle swelling and bacterial number in joint tissue,
whereas the Mann–Whitney U test was used for PMN
infiltration and overall lesion. All categories were
negative for uninfected control C3H and C3H-
IFNAR12/2 mice, injected with BSK media, and are
not shown in the figure. n $ 9 mice for each group,
pooled from two independent experiments. *p , 0.05.
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Relative contribution of radiation-sensitive and resistant cells
to the type I IFN-dependent development of Lyme arthritis
The results of Fig. 2 suggest that a mixture of cell lineages in the
joint tissue may determine both the magnitude and breadth of the
IFN response to B. burgdorferi and the severity of subsequent
arthritis in C3H mice. To address the relative contribution of
resident cells of the joint, such as endothelial cells and fibroblasts,
and infiltrating hematopoietic cells to the type I IFN-dependent
development of arthritis, we developed reciprocal radiation chi-
meras between C3H and C3H IFNAR12/2 mice, using rapid re-
constitution protocol to allow B. burgdorferi infection of mice ,8
wk of age. The efficiency of reconstitution of hematopoietic cells
in the chimeras was determined by staining for IFNAR1 (28),
described in Materials and Methods. Reconstitution of irradiated
C3H mice with syngeneic splenocytes (C3H⇒C3H) resulted in
severe arthritis following infection by B. burgdorferi, whereas
infection of irradiated C3H IFNAR12/2 mice reconstituted with
syngeneic splenocytes (IFNAR12/2⇒IFNAR12/2) displayed less
severe arthritis (Fig. 3), and similar to nonirradiated mice in Fig. 1.
Reconstitution of C3H mice with splenocytes from IFNAR12/2
mice or reconstitution of IFNAR12/2 mice with C3H splenocytes
resulted in arthritis of intermediate severity following infection,
shown for joint measurement and overall lesion score (Fig. 3).
Control of B. burgdorferi was not significantly different in the
treated animals, demonstrating that reconstitution was adequate
for host defense (Fig. 3). That arthritis severity in the chimeras
was intermediate compared with that observed for wild-type or
IFNAR12/2 mice implies that both radiation-resistant cells of the
joint and radiation-sensitive hematopoietic cells contribute to the
IFN receptor-dependent autocrine/paracrine effect that drives the
severe arthritis of C3H mice.
Ex vivo identification of cell lineages in the joint tissue of naive
mice capable of initiating and responding to the type I IFN
response
The radiation chimera experiment of Fig. 3 implicated both he-
matopoietic and resident cells of the joint in the type I IFN-
FIGURE 2. IFN-g provides partial compensation for type I IFN in infected joint tissue and in bonemarrowmacrophage cultures fromC3H IFNAR12/2mice.
(A) RT-PCR analysis of transcripts in joint tissue at 7 d postinfection (Borrelia) or mock infection of C3H IFNAR12/2mice (media) treated with anti–TNF-a,
anti–IFN-g, or isotype control IgG1, as described inMaterials andMethods (n = 5). The following transcripts were analyzed and normalized to b-actin:Cxcl10,
Oasl2, Igtp, andGbp2. (B) Effect of exogenous IFN-g on transcriptional induction of IFN profile in BMDM fromC3H andC3H IFNAR12/2mice incubatedwith
B. burgdorferi, IFN-g,B. burgdorferi plus IFN-g, or media alone for 6 h. RT-PCR analysis of IFN profile transcripts (Cxcl10,Oasl2, Igtp, andGbp2), normalized
to b-actin. (C) B. burgdorferi-induced secretion of bioactive type I IFN protein in culture supernatants of C3H and C3H IFNAR12/2 BMDM, collected at 24 h.
Supernatants were applied to type I IFN reporter cell line for IFN bioassay, as described inMaterials andMethods. Transcription analysis of Ifnb at 6 h from same
experiment is shown for comparison, and Tnfa transcripts are included as viability and responsiveness control. Data are representative of two independent
experiments. Statistical significance among groups (transcript analysis) or between experimental and control groups (IFN bioassay) is shown (*p , 0.05).
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dependent development of Lyme arthritis. BMDM and other
myeloid cells have been identified as sources of IFN when incu-
bated with B. burgdorferi (Fig. 2B) (13, 34–36). Although it is
likely that the complex milieu of the joint tissue facilitates co-
operation among a variety of cell types, it is also possible that
myeloid cells, such as macrophages, are uniquely endowed with
the ability to internalize and sense B. burgdorferi pathogen-asso-
ciated molecular patterns, which lead to the initiation of the IFN-
responsive transcriptional profile (36–38). To identify the relative
ability of hematopoietic cells and nonhematopoietic cells of the
joint to initiate the IFN profile, single-cell suspensions were re-
covered from the joints of naive C3H mice following gentle di-
gestion, and fractionated into CD45+ and CD452 populations by
magnetic bead separation. Approximately 20% of the cells in the
unfractionated group were CD45+, and this increased to 75–80%
following CD45 enrichment, as determined by flow cytometry
(Fig. 4A). Cells from the three populations were cultured for 6 h in
the presence of B. burgdorferi, IFN-b, or B. burgdorferi plus IFN-b.
The expression of the NF-kB–dependent transcript Tnfa served
as a control for viability, as its production has been previously
characterized in both myeloid and endothelial cells treated with B.
burgdorferi (22, 39). By this measure, both CD45+ and CD452
fractions were viable and capable of responding to B. burgdorferi
(Fig. 4B). Cell viability was further confirmed by the response to
IFN-b alone, as both CD45+ and CD452 fractions upregulated the
early IFN-inducible transcripts Cxcl10 and Tyki following this
treatment (Fig. 4C, 4D) (40). This also points to the potential
involvement of both fractions in the amplification stage of the IFN
response. In contrast, only the CD45+ cells were capable of up-
regulating Cxcl10 and Tyki in response to B. burgdorferi alone
(Fig. 4C, 4D), indicating novel contribution of CD45+ cells in
triggering the IFN-inducible profile. As we previously demon-
strated that the IFN profile at 1 wk postinfection is also observed
in infected C3H scid mice (13), these results strongly implicate
a myeloid lineage cell as initiator of the IFN response resulting in
activation of large numbers of resident cells that amplify the re-
sponse.
Assessment of changes in cellular composition and activation
in B. burgdorferi-infected joint tissue
The unique ability of CD45+ cells to initiate the IFN profile ex
vivo, and the ready induction of this response in BMDM cultures,
suggested that infiltrating myeloid cells might be the driving force
behind the IFN response to B. burgdorferi in vivo.
Ly6C+-expressing inflammatory monocytes have recently been
implicated in both the beneficial type I IFN response to viral in-
fection and in its pathological production in chronic disease such
as SLE (41, 42). Therefore, the composition and infiltration of
Ly6C+ myeloid-lineage cells to the joint tissue of C3H mice were
FIGURE 3. Radiation chimeras between C3H and IFNAR12/2 mice
reveal contribution of both resident cells and cells of hematopoietic origin
to proarthritic IFN response. Reciprocal radiation chimeras between C3H
and C3H IFNAR12/2 mice were generated, as described in Materials and
Methods. Mice were infected with B. burgdorferi 3 wk following recon-
stitution, and arthritis severity was assessed at 4 wk postinfection, shown
for change in ankle measurement and overall lesion score. Direction of
transplantation from donor to recipient is indicated on the figure. Results
are pooled from two separate experiments, with$10 mice in each infected
mouse group. B. burgdorferi numbers at 4 wk postinfection were similar
in all mice. Uninfected chimeras did not display ankle abnormalities or
B. burgdorferi DNA in tissues. Statistical significance among groups (*p,
0.05) is indicated.
FIGURE 4. Potential contribution of hematopoietic
and nonhematopoietic cells to the initial IFN response
to B. burgdorferi in joints of C3H mice. Enrichment
of leukocytes in the CD45+ fraction was confirmed
by flow cytometry (A) with significant change from
unfractionated indicated (*p , 0.05). RT-PCR of
transcripts for Tnfa (B), Cxcl10 (C), and Tyki (D)
identified populations responsive to B. burgdorferi,
IFN-b, and combined treatment, and were normalized
to b-actin. Only CD45+ cells displayed significant
upregulation of the IFN-inducible transcripts Cxcl10
and Tyki in response to B. burgdorferi alone, as indi-
cated. Results are representative of three separate
experiments, with n = 3. Statistical significance be-
tween experimental and control groups (*p , 0.05) is
indicated.
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determined by flow cytometry assessment of populations released
from the joint tissue over time: PMN leukocytes were defined
as GR1highLy6CdimCD11bhighCD45+, macrophages were GR12
Ly6C2F4/80+CD11bhighCD45+, and inflammatory monocytes
were GR1dimLy6ChighCD11bhighCD45+. Increases in all three my-
eloid lineage populations were seen at days 11 and 14 postinfection
relative to uninfected mice, with macrophages and PMNs domi-
nating the inflammatory cell infiltrate (Fig. 5A). The increases in
these lineages at day 11 postinfection were similar between C3H
and C3H IFNAR12/2 mice, indicating the recruitment or ex-
pansion of these cells was not dependent on type I IFN signaling.
Importantly, the Ly6C+ population showing the greatest increase
following infection in both C3H and C3H IFNAR12/2 mice was
the inflammatory monocyte; however, this increase was not ob-
served until day 11 of infection and was still elevated at day 14. Of
note, there was no increase in any of the myeloid cell populations
at day 7 postinfection, the time point previously and in this study
associated with the peak of the IFN response (Fig. 5A). This
striking result indicated that the induction of the IFN profile was
not dependent on recruitment of myeloid cells from the blood or
other tissues; rather, it suggested that the initiator of the IFN re-
sponse might be a myeloid cell endogenous to the joint tissue.
This could include macrophages naturally present within in the
joint space or synoviocytes of the macrophage lineage.
That Ly6C+ myeloid lineage cells contribute to the ultimate
development of arthritis is clearly suggested by the dramatic in-
crease in these populations by day 11 postinfection. These cells
may also be important in host defense, as their presence at
14 d coincides with our previous identification of upregulation of
transcripts associated with host defense at this time point (9). In
support of this concept, there was a marked shift in the ratio of
PMN to macrophage presence at day 14 postinfection of wild-type
mice that did not occur in the absence of IFN signaling (Fig. 5A),
consistent with published findings in other experimental models of
the role of type I IFN in maturation of the myeloid cells in lo-
calized tissues (42). It is interesting to speculate on the possible
contribution of this difference to the development of more severe
arthritis in C3H mice than in C3H IFNAR12/2 mice.
Changes in cellularity of resident cells of the joint tissue were
also found, as shown for the increase in both endothelial cells and
fibroblasts in joints of infected mice (Fig. 5B). Endothelial cell
(CD452CD31+) and fibroblast (CD452CD312CD90+CD29+)
numbers were increased by days 11 and 14 postinfection in joints
from both C3H and C3H IFNAR12/2 mice (Fig. 5B). Increases in
these populations were similar in the two mouse strains, indicating
lack of dependence on type I IFN. The percentages of endothelial
cells and joint fibroblasts that displayed activation markers
(VCAM1+ICAM1high) were increased by day 11 postinfection,
and continued to be elevated through day 14. The similarity in
activation marker expression by endothelial cells and joint fibro-
blasts from C3H and C3H IFNAR12/2 mice indicated that this
event was also not dependent on type I signaling (Fig. 5B).
FIGURE 5. Infiltration and expansion of mye-
loid cells, endothelial cells, and fibroblasts in the
joint tissue of B. burgdorferi-infected C3H mice.
(A) Single-cell suspensions were analyzed for the
presence of PMNs (GR1+Ly6C+ CD11b+CD45+),
inflammatory monocytes (Ly6ChighGR12CD11b+
CD45+), and macrophages (GR12Ly6Cdim F4/80+
CD11b+CD45+) by flow cytometry at days 0
(media), 7, 11, and 14 postinfection with B. burg-
dorferi. Mean6 SEM are indicated, with n = 3. (B)
Single-cell suspensions were analyzed for fibro-
blasts (CD452CD312CD90+CD29+) or endothelial
cells (CD452CD31+) by flow cytometry at days
0 (media), 7, 11, and 14 of infection. Activated
cells were identified as VCAM1+ICAM1high.
Statistically significant differences were found at
11 and 14 d of infection relative to uninfected
mice, for both the C3H and IFNAR2/2 mice, but
differences were not found between the two
mouse genotypes at any time point (*p , 0.05)
indicated. These results are representative of two
separate experiments, n = 3.
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However, the potential participation of these cells in the amplifi-
cation of the IFN response and participation in other proin-
flammatory cascades in C3H mice is clearly supported by the
expression of classic activation markers. Thus, the complex en-
vironment of the infected joint tissue provides opportunity for
activation of multiple cell types that contribute to the IFN-
dependent and IFN-independent events associated with the de-
velopment of Lyme arthritis.
Ex vivo analysis of IFN-responsive cells sorted from the joint
tissue of B. burgdorferi-infected mice
The presence of activated endothelial cells and fibroblasts in the
joint tissue of infected C3Hmice suggested that they could be early
participants in the response to B. burgdorferi, in addition to res-
ident myeloid lineage cells (Figs. 4, 5). To quantitatively analyze
the IFN response within the infected joint tissue, single-cell sus-
pensions were prepared by enzymatic digestion, stained with
lineage markers, separated by FACS, and RNA recovered for
transcript analysis at 0, 7, 11, and 14 d postinfection. The fol-
lowing cell types were identified for cell sorting: myeloid cells
were CD45.2+Cd11b+; lymphoid cells were CD45.2+CD11b2
(B220+ or TCRb+); endothelial cells were CD452CD31+ with
many of these also expressing high levels of Ly6C; and a final
group was comprised of a heterogeneous mixture of stromal cell
types, such as fibroblasts, chondrocytes, and smooth muscle cells
that were CD452CD312. A subset of this group was CD90+
CD29+, indicative of joint fibroblasts, including synovial fibro-
blasts, and some of which were also Ly6C+ (data not shown). Pilot
studies confirmed that the earliest time to reproducibly capture the
IFN profile in cells sorted from the infected joint was day 7 of
infection, which coincides with the earliest time point at which
B. burgdorferi 16S rRNA can be reliably detected in this tissue (data
not shown). IFN-inducible transcripts peaked at 7 d postinfection, in
both the unfractionated and each of the sorted populations of joint
cells, shown for Cxcl9, Iigp, Gbp2, and Oasl2 (Fig. 6). IFN-
induced transcript levels receded dramatically by day 11 postin-
fection, similar to uninfected levels. In addition to the expected
contribution of myeloid cells and lesser contribution of lymphoid
cells, endothelial and fibroblast-enriched fractions displayed ro-
bust upregulation of the IFN-inducible transcripts. Although the
importance of synovial fibroblasts in the pathogenesis of RA is
well appreciated (43), the dominating role of endothelial cells and
fibroblasts in the tissue response to B. burgdorferi infection has
not been previously demonstrated. The precise and synchronized
timing of the IFN response in all cell lineages further indicates
carefully orchestrated expression patterns in the joint tissue.
The results of Fig. 6 implicated both endothelial cells and joint
fibroblasts in the early response to B. burgdorferi in the joint
tissue. An interesting observation from the transcript analysis in
Fig. 6 is the finding that both Iigp and Gbp2 were constitutively
expressed in endothelial cells at higher concentrations than found
in myeloid or fibroblast-enriched cells. This suggested the pos-
sibility that endothelial cells of the joint tissue were poised to
respond to blood-borne pathogens or inflammatory mediators.
Therefore, activation states of endothelial cells and synovial
fibroblasts were further dissected with more specific staining
reagents, and the FACS separation was repeated for joint tissue
from uninfected and day 7 infected C3H mice. Leukocytes were
identified as CD45+, endothelial cells were identified as CD31+
CD452, and in this protocol joint fibroblasts were isolated using
the markers CD452 and CD312 to remove hematopoietic and
endothelial cells, followed by enrichment for fibroblasts, including
synovial fibroblasts, using CD90+CD29+ (Fig. 7A) (44). The
fidelity of the sorting protocol was confirmed by lineage-specific
transcript analysis and revealed enrichment of CD45 transcripts
only in leukocytes, CD31 enrichment in endothelial cells, CD90
(Thy1) enrichment in fibroblasts and leukocytes, and enrichment
of fibronectin in joint fibroblasts and other cell types, which were
not defined in our analysis, but include epithelial cells, chon-
drocytes, and smooth muscle cells (Fig. 7B). Transcripts from
Mmp3 were also only identified in the joint fibroblast and other
fractions (data not shown), further evidence that this represents
a functionally discrete subset in the joint tissue. Similar confir-
mation of sorting fidelity was obtained for the lineage-sorted
fractions used in Fig. 6 (data not shown). The activation status
of endothelial cells and fibroblasts in the joint at the critical day 7
time point was studied following FACS recovery of cells stained
for VCAM1, ICAM1, and PECAM1. Endothelial cells demon-
strated increased staining intensity and transcriptional upregu-
lation for all three activation markers at day 7 postinfection,
FIGURE 6. Ex vivo identification of endothelial
cells and fibroblasts as major contributors to the IFN
response of infected C3H joints. FACS analysis of cells
released from joint tissue of C3H mice infected for
0 (media), 7, 11, and 14 d. Single-cell suspensions of
joint tissue were prepared for lineage staining, and
FACS was used to collect and quantify lineages. RT-
PCR analysis of sorted lineages at each time point (n =
3). Myeloid cells (CD45+CD11b+), lymphoid cells
(CD45+CD11b2, TCRb+, or B220+), endothelial cells
(CD452CD31+), and fibroblast-enriched cells (CD452
CD312) were sorted simultaneously. Expression of
IFN-inducible transcripts, Gbp2, Iigp, Cxcl9, and
Oasl2, was normalized to b-actin. Statistical signifi-
cance between experimental and control groups (*p ,
0.05) is indicated.
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whereas joint fibroblasts showed increased expression of Vcam1
and Icam1 (and do not express Pecam1) (Fig. 8A, 8B). These
data indicate that cellular activation precedes proliferation of
endothelial cells and fibroblasts shown earlier (Fig. 5B), and
demonstrate strong correlation between transcript induction and
protein expression at day 7 postinfection. Interestingly, these
VCAM1+ICAM1+ fibroblasts were also Ly6C+ (data not shown),
and may constitute fibroblast-like synoviocytes implicated in RA
(43, 44).
Transcriptional analyses of the highly enriched endothelial and
fibroblast fractions from the joint further supported their contri-
bution to the IFN profile at day 7 (Table II). Endothelial cells and
fibroblasts were found to be major contributors of the classic IFN-
inducible transcripts Gbp2, Iigp, and Oasl 2, as well as the IFN
transcriptional activator Stat1. The contribution of endothelial
cells and fibroblasts to the B. burgdorferi-induced IFN response is
striking, and previously unrecognized, although human endothe-
lial cell cultures were previously shown to respond to B. burg-
FIGURE 7. Characteristics of endothelial cells and fibroblasts recovered from joints of C3H mice at day 7 postinfection display markers of activation.
(A) Flow cytometry analysis of single-cell suspensions from joint tissue of uninfected and day 7 infected C3H mice. Fibroblasts were identified as CD452
CD312CD90+CD29+, whereas endothelial cells were CD452CD31+. Cell populations shown for a single mouse, representative of four. (B) Accuracy of
sorting demonstrated by transcript analysis of lineage-specific markers in indicated FACS-recovered populations: CD45, CD90, CD31, Fibronectin, from
uninfected (media) and mice infected 7 d earlier with B. burgdorferi (day 7).
FIGURE 8. Endothelial cells and fibroblasts display
activation markers at day 7 of infection. (A) Mean
fluorescence intensity (MFI) of ICAM1, VCAM1, and
PECAM1 on fibroblasts (CD452CD312CD90+CD29+)
and endothelial cells (CD452CD31+) recovered from
joint tissue of uninfected mice and mice at day 7 of
infection. (B) Transcript analysis from cells recovered
by FACS analysis of uninfected and day 7 infected
mice. RT-PCR performed as described, n = 4. Results
representative of two independent experiments. Sta-
tistical significance between uninfected and infected
cell types was determined by Student t test, and is
shown (*p , 0.05).
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dorferi through a classic NF-kB–dependent signaling cascade
(45). Further analyses of the transcriptional response to B. burg-
dorferi revealed both joint fibroblasts and endothelial cells to be
the dominant sources of chemokines (Table III), with joint fibro-
blasts supplying the PMN and monocyte-recruiting Cxcl1, Cxcl2,
Ccl2, and Ccl8, and endothelial cells serving as the primary source
of the CXCR3-interacting chemokines Cxcl9 and Cxcl10, impor-
tant in recruiting NK and T cells. This coincides with an increase
in the expression of the classic activation markers VCAM1,
ICAM1, and PECAM1 by fibroblasts and endothelial cells (Fig.
8), which would further contribute to the recruitment of inflam-
matory cells. Also of note is the production of Cxcl1 and Cxcl10
by endothelial cells, important stimulants for neutrophils and ac-
tivated neutrophils, respectively. The unique contribution of leu-
kocytes to Cxcl13 recruitment of B lymphocytes may be important
in the resolution of infection and disease. It is particularly inter-
esting in light of the strong association of CXCL13 with tissue-
specific infection by B. burgdorferi in humans (46, 47).
Integration of our ex vivo analysis of the early responses of the
infected joint tissue with characteristics of the arthritic lesions at
28 d postinfection has allowed development of a dynamic model for
B. burgdorferi-induced arthritis development in C3H mice (Fig. 9).
Two phases of arthritis development are shown in this model, with
the first phase incorporating the initiation of type I IFN production
and the upregulation of other proinflammatory molecules, and the
second phase depicting the progression to the arthritic lesion. The
involvement of myeloid cells, endothelial cells, and fibroblasts is
depicted, with upregulation of chemokines by fibroblasts and
synoviocytes providing the key stimulus for arthritis development.
Discussion
Previously, we noted a transient and early induction of type I IFN
signature transcriptional response in the joint tissue of B. burg-
dorferi-infected C3H mice and determined this to be a predictor of
the severity of Lyme arthritis in this mouse strain (9). Subse-
quently, we discovered that blocking the early type I IFN signaling
cascade by systemic administration of mAb muted the arthritic
response in C3H mice at 4 wk postinfection, thus formally cou-
pling the induction of type I IFN to Lyme arthritis (13). Together
these findings defined a model by which joint-localized bacteria
triggered a provocative burst of type I IFN that in turn established
an inflammatory cascade that resulted in severe arthritis 2–3 wk
later (Fig. 9). The identification of the cellular interactions required
to trigger the response in the joint tissue was important in under-
standing the initiation of this response in C3H mice. A variety of
different cell types have been identified as initiators of type I IFN
in other infectious and pathological conditions, suggesting that
in vivo analysis would be required to characterize the cells re-
sponsible for initiating and executing this response in the joint.
To achieve a more rigorous assessment of type I IFN-dependent
signaling on the development of Lyme arthritis, the IFNAR1 gene
disruption was crossed onto the C3H mouse. Experiments with this
mouse strain confirmed the importance of type I IFN signaling in
the development of arthritis (Fig. 1), but also confirmed the im-
portance of additional, IFN-independent pathways in the maximal
arthritis of infected C3H mice, in line with the documented
multigenic nature of this arthritis (24, 30). The development of the
C3H IFNAR12/2 mouse permitted the generation of reciprocal
radiation chimeras with C3H mice. These experiments revealed
contributions of both hematopoietic and mesenchyme-derived
cells to the IFN-dependent portion of arthritis development (Fig.
3), consistent with the broad expression of the type I IFN receptor
and its importance in promoting the antiviral state in most lineages
(16). Interestingly, type I IFN signaling was not required for ef-
fective control of bacteria number in joint or other tissues, a con-
trast from findings with IFN-g (Figs. 1, 3) (10, 11, 48). This
observation raises the possibility that the type I signaling pathway
could provide a novel therapeutic target for Lyme arthritis without
disrupting the efficacy of ongoing antibacterial treatments.
It is generally accepted that B. burgdorferi can enter tissues
following hematogenous spread, and that it is the response of the
host to bacteria in the tissue that initiates an inflammatory re-
sponse (5, 49). Therefore, a more precise ex vivo analysis of cells
from the joint tissue was employed to assess the cellular dynamics
of the response to B. burgdorferi invasion. Consistent with the
radiation chimera experiment, both hematopoietic cells and
fibroblasts and endothelial cells of the joint contributed to the
robust IFN profile in infected joint tissue (Figs. 4, 6, Tables II, III).
Evaluation of cells recovered from the naive joint revealed a much
more limited ability to generate an IFN response to B. burgdorferi:
only CD45+ cells had this capability. However, both CD45+ and
CD452 cells responded to exogenous IFN-b by amplifying the
production of IFN-inducible transcripts, indicating their potential
contribution to the arthritis-associated response. Both CD45+ and
CD452 cells of the naive joint upregulated Tnfa in response to B.
burgdorferi in vitro, simulating the potential contribution of IFN-
independent signaling pathways during infection.
The ability of human and murine macrophages, monocytes, and
dendritic cells to initiate a type I IFN response when stimulated
with B. burgdorferi in vitro has been clearly documented; how-
Table II. Endothelial cells and fibroblasts are major contributors of IFN-inducible transcripts in joints of B.
burgdorferi-infected C3H mice
IFN-Inducible Genes
Cell Type Treatment Gbp2 Iigp Oasl2 Stat1
Leukocytea Media 2 6 0.6b ND 3 6 0.8 10 6 2.9
Infected 29 6 3.3c 13 6 3.7 19 6 5.6 21 6 4.2
Endothelial Media 36 6 9.0 116 6 30.1 3 6 1.7 13 6 5.7
Infected 447 6 22.3 514 6 62.9 44 6 7.1 160 6 12.7
Fibroblast Media 21 6 2.9 11 6 1.9 3 6 1.5 6 6 1.7
Infected 273 6 39.9 188 6 20.6 38 6 11.1 71 6 23.8
Other Media 7 6 1.3 2 6 0.9 2 6 1.0 12 6 2.4
Infected 112 6 19.6 53 6 15.9 14 6 4.7 71 6 15.5
Unsorted Media 28 6 1.5 82 6 6.2 4 6 0.5 10 6 0.4
Infected 134 6 15.2 149 6 20.7 30 6 1.6 53 6 7.8
aRNA prepared from lineage-sorted joint cells at day 7 of infection.
bMean 6 SE for samples from four mice, normalized to b-actin.
cBolded numbers indicate greater induction compared with mice treated with media alone, p , 0.05.
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ever, to our knowledge, this is the first study to directly assess the
potential of cells of the joint tissue to mount this response. Our
results are most consistent with a resident mononuclear cell ini-
tiating the IFN profile following phagocytosis of B. burgdorferi
and processing Borrelia ligands capable of activating cellular
sensors. Numerous laboratories studying the IFN response to B.
burgdorferi have identified MyD88-dependent sensors, particu-
larly TLR7/8, and MyD88-independent, IFN regulatory factor-3–
dependent sensors capable of inducing type I IFN in cultures of
mouse and human mononuclear cells (34–37, 50, 51). B. burgdor-
feri ligands implicated in this response include RNA, lipoproteins,
and secreted bacterial components (25, 34, 36, 52). Interestingly,
the Ly6C+ inflammatory monocytes, whose recruitment has been
implicated in the IFN response in other systems (41, 42, 53), were
not increased in joint tissue until day 11 postinfection and,
therefore, this expansion was not required for the day 7 IFN signal
amplification (Fig. 5). The appearance of Ly6C+ cells may have
greater impact on later responses to B. burgdorferi, which shift to
classic NF-kB–dependent production of cytokines and chemo-
kines on days 11 and 14 postinfection (9).
Ex vivo analysis of cells recovered from joints of infected C3H
mice revealed cell types contributing to the IFN transcriptional
signature at day 7 postinfection. Whereas the contribution of
myeloid cells to the profile was expected, the magnitude of the
contribution made by endothelial cells and fibroblasts of the joint
tissue was a surprise. Based on our finding that CD452 cells of
joint of naive mice did not upregulate the IFN profile in response
to B. burgdorferi alone but did respond well to exogenous IFN-b,
we suspect that the robust responses of endothelial cells and joint
fibroblasts from infected mice reflect the combined effects of B.
burgdorferi and the autocrine/paracrine activity of type I IFN,
together resulting in exuberant production of amplified type I IFN
and downstream products (Figs. 4, 6, 8, Table II). The upregula-
tion of Stat1 transcripts at day 7 postinfection is consistent with
the importance of the IFN receptor-dependent amplification stage
of this response, even at this early time point.
Of particular importance to the development of Lyme arthritis
was the finding that fibroblasts of the joint were the major producers
of chemokines involved in recruitment of the hallmark cell of Lyme
arthritis, the PMN ( Table III). Consistent with these data is the
documented role of fibroblast-like synoviocytes in promoting in-
flammation in RA (54). Brown and colleagues (55, 56) previously
demonstrated the critical role of PMN-recruiting chemokines and
their receptors in the development of Lyme arthritis, with mono-
cyte chemokines playing an analogous role in carditis develop-
ment. Our results point to the activated fibroblast (likely synovial)
as the source of PMN and monocyte-recruiting chemokines in
Lyme arthritis development and resolution. The relative contri-
bution of fibroblasts occupying the joint space versus synoviocytes
comprising the membranous synovial sheath could not be de-
termined in this study. These findings indicate that activation of
endothelial cells and fibroblasts in the joint sets the stage for
subsequent recruitment of arthritis-defining inflammatory cells,
as shown in phase 1 of Fig. 9. The importance of additional in-
flammatory pathways in the sustained recruitment resulting in
arthritis development is suggested by the residual Lyme arthritis
seen in C3H IFNAR12/2 mice as well as the ability of CD452
cells from the joint tissue to upregulate transcripts for TNF-a in
response to B. burgdorferi. The development of severe Lyme ar-
thritis is clearly influenced by multiple pathways activated si-
multaneously, with the full-blown lesion observed in C3H mice
reflecting the combined effects. Fundamental to our model is the
requisite involvement of joint-localized bacteria in every stage of
lesion development.
Our findings suggest a model by which B. burgdorferi exits the
vascular endothelium and enters the joint tissue, potentially en-
countering several types of cells (Fig. 9) (57, 58). Endothelial cells
may be the first to encounter B. burgdorferi as it exits the blood,
and human endothelial cells are known to engage TLR-MyD88–
dependent signaling in response to B. burgdorferi (45). Fibroblasts
are also abundant components of connective tissue of the joint,
and the interaction of B. burgdorferi with synovial fibroblasts,
fibrocytes, and extracellular matrix components of connective
tissue has been well established (59, 60). Myeloid cells residing in
the joint, possibly including macrophage-like synoviocytes and
tissue macrophages, appear to trigger the type I IFN response (Fig.
9). This response most likely requires phagocytosis of B. burg-
dorferi and liberation of bacterial components that result in IFN
regulatory factor-3 activation and type I IFN induction (25, 35, 36,
38, 50). Once type I IFN production is initiated, numerous cell
types of the joint, particularly endothelial cells and synovial
fibroblasts, engage the type I IFN receptor and join the IFN sig-
nature response, leading to a positive feedback that amplifies the
signaling cascade and sets the stage for the development of severe
Lyme arthritis, phase 2 (Fig. 9).
These observations are striking due to the association of ex-
cessive production of type I IFN with other inflammatory-based
diseases, including patients with SLE and those receiving thera-
peutic doses of IFN-ab for hepatitis and multiple sclerosis (14–16,
61). The recent recognition of an IFN signature response in a
Table III. Endothelial cells and fibroblasts upregulate various chemokine transcripts in joints of B. burgdorferi-infected C3H mice
Chemokines
T, NK Cells Neutrophils B Cells Monocytes, Dendritic Cells
Cell Type Treatment Cxcl9 Cxcl10 Cxcl1 Cxcl2 Cxcl13 Ccl2 Ccl8
Leukocytea Media 0.7 6 0.4b 4 6 2.4 3 6 0.8 54 6 13.2 0.3 6 0.3 21 6 3.4 ND
Infected 5 6 2.4 13 6 4.9 9 6 4.0 43 6 10.8 6 6 0.9 20 6 8.2 0.2 6 0.1
Endothelial Media 7 6 2.9 9 6 8.6 6 6 3.1 4 6 2.4 ND 2 6 1.3 ND
Infected 156 6 11.2c 124 6 21.4 25 6 3.6 4 6 1.2 1.3 6 1.3 3 6 3.0 ND
Fibroblast Media 0.5 6 0.5 3 6 1.6 61 6 3.2 9 6 3.0 0.9 6 0.3 57 6 8.5 0.3 6 0.3
Infected 87 6 33.0 119 6 15.9 233 6 30.6 49 6 16.3 7 6 3.5 226 6 34.1 2.4 6 0.6
Other Media ND 2 6 1.9 13 6 3.3 3 6 2.0 ND 6 6 0.8 ND
Infected 16 6 8.5 44 6 7.7 36 6 5.9 7 6 3.8 ND 22 6 12.3 0.6 6 0.6
Unsorted Media 4 6 0.5 7 6 0.4 23 6 1.1 16 6 3.3 0.1 6 0.06 23 6 0.8 0.2 6 0.05
Infected 42 6 7.8 42 6 4.2 31 6 1.9 24 6 2.2 6 6 2.2 29 6 2.4 0.5 6 0.1
aRNA prepared from lineage-sorted joint cells at day 7 of infection.
bMean 6 SE for samples from four mice, normalized to b-actin.
cBolded numbers indicate greater induction compared with mice treated with media alone, p , 0.05.
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subgroup of RA patients that fail to respond to targeted TNF-a
blockade further suggests our findings may be broadly applicable
to newly recognized patient groups (18, 19, 62). We propose the
IFN-dependent Lyme arthritis in C3H mice to be a model to study
the complex interactions that result in tissue-specific and systemic
activation of pathological concentrations of type I IFN. We further
propose that the similarities with RA, particularly the involvement
of synovial fibroblasts in the amplification of the inflammatory
response and recruitment of inflammatory cells, are highly rele-
vant to disease development, and that understanding the dynamics
of initiating and amplifying populations in pathological responses
may have broad implications for inflammatory joint diseases.
FIGURE 9. Proposed mechanism of injury in joint tissue of C3H mice infected with B. burgdorferi. Phase 1: Initiation of the localized inflammatory
response. (A) Spirochetes migrate to joint tissue, triggering activation of endothelial cells and fibroblasts and upregulation of adhesion molecules. (B)
Resident myeloid lineage cells, such as macrophages, phagocytose B. burgdorferi, triggering production of IFN-b (C). (D) IFN-b signal is amplified in an
autocrine/paracrine fashion, involving a large number of cell types, including endothelial cells and fibroblasts. (E) Synoviocytes and endothelial cells
produce a variety of chemokines, leading to a chemotactic gradient. Increased adhesion molecule expression potentiates leukocyte migration into tendon
sheath and joint capsule. Phase 2: Progression to the joint lesion characteristic of Lyme arthritis (14–28 d). (F) Increased expression of cell adhesion
molecules on vascular endothelial cells promotes attachment and extravasation of leukocytes into the extracellular matrix, and myeloid hyperplasia. (G)
Fibroblast hyperplasia and increased vascularization develop within the tendon sheath, as well as (H) synoviocyte hyperplasia. IFN-b response is muted by
this time point; thus, sustained inflammation most likely reflects effects of classic proinflammatory pathways activated by persisting B. burgdorferi. (Figure
courtesy of James F. Zachary, University of Illinois-Urbana.)
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MICRORNA-146a PROVIDES FEEDBACK REGULATION OF LYME ARTHRITIS 
BUT NOT CARDITIS, DURING INFECTION WITH BORRELIA BURGDORFERI 
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Abstract 
 MicroRNAs have been shown to be important regulators of inflammatory and 
immune responses and are implicated in several immune disorders, including systemic 
lupus erythematosus and rheumatoid arthritis, but their role in Lyme borreliosis remains 
unknown. We performed a microarray screen for expression of miRNAs in joint tissue 
from three mouse strains infected with Borrelia burgdorferi. This screen identified 
upregulation of miR-146a, a key negative regulator of NF-κB signaling, in all three 
strains, suggesting it plays an important role in the in vivo response to B. burgdorferi. 
Infection of B6 miR-146a-/- mice with B. burgdorferi revealed a critical nonredundant 
role of miR-146a in modulating Lyme arthritis without compromising host immune 
response or heart inflammation. The impact of miR-146a was specifically localized to the 
joint, and did not impact lesion development or inflammation in the heart. Furthermore, 
B6 miR-146a-/- mice had elevated levels of NF-κB-regulated products in joint tissue and 
serum late in infection. Flow cytometry analysis of various lineages isolated from 
infected joint tissue of mice showed that myeloid cell infiltration was significantly greater 
in B6 miR-146a-/- mice, compared to B6, during B. burgdorferi infection. Using bone 
marrow-derived macrophages, we found that TRAF6, a known target of miR-146a 
involved in NF-κB activation, was dysregulated in resting and B. burgdorferi-stimulated 
B6 miR-146a-/- macrophages, and corresponded to elevated IL-1β, IL-6, and CXCL1 
production. This dysregulated protein production was observed in macrophages treated 
with IL-10 prior to B. burgdorferi stimulation. Peritoneal macrophages from B6 miR-
146a-/- mice also showed enhanced phagocytosis of B. burgdorferi. Together, these data 
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show that miR-146a-mediated regulation of TRAF6 and NF-κB, and downstream targets 
such as IL-1β, IL-6, and CXCL1, are critical for modulation of Lyme arthritis during  




 Lyme Disease is caused by infection with the bacteria Borrelia burgdorferi, is 
transmitted through infected deer ticks (Ixodes scapularis), and often leads to arthritis 
that can persist, even after antibiotic treatment. Here, we have identified a microRNA that 
is critical in modulating Lyme arthritis, but not carditis. This microRNA, miR-146a, is a 
negative regulator of NF-κB signaling, known to be important in host defense against 
pathogens, and long suspected to play a role in Lyme arthritis development. Mice lacking 
miR-146a develop more severe arthritis and show signs of hyperactive NF-κB activation 
during the persistent phase of infection. Heart manifestations of disease were not altered. 
Furthermore, this severe arthritis is independent of host defense, since these mice are 
better able to clear invading bacteria in joints, and bacterial numbers are similar in heart 
and ear tissue. We identified TRAF6 as an important target of miR-146a-mediated NF-
κB regulation of pro-inflammatory cytokines IL-6 and IL-1β, as well as chemokines 
CXCL1 and CXCL2. Our data demonstrate the importance of maintaining appropriate 
regulation of amplitude and resolution of NF-κB activation during Borrelia burgdorferi 
infection, and provide a novel model for elucidating the role of NF-κB in Lyme arthritis  
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Introduction 
Lyme Disease is caused by infection with Borrelia burgdorferi, a tick-borne 
spirochete [1], and is the most common vector-borne disease in the United States with an 
estimated 300,000 cases per year [2]. Often, infection leads to acute arthritis in humans. 
Clinical manifestations of Lyme arthritis include inflammatory cell infiltration, edema, 
synovial hyperplasia, and remodeling of bone and connective tissue [3,4]. In some cases, 
infection can induce autoimmunity, despite treatment with antibiotics [5]. The reason 
why arthritis fails to resolve remains poorly understood, but is believed to be the result of 
dysregulation of host immune response to infection [6]. 
Several inbred mouse strains exhibit varying degrees of disease severity similar to 
human patients [7,8]. Whereas the C57BL/6 (B6) mouse strain develops mild arthritis, 
C3H and various knockout strains, such as B6 IL10-/- mice, develop moderate to severe 
arthritis [7,9]. Furthermore, the intensity of the inflammatory response for a given 
spirochete burden varies greatly among strains, implicating host immune response as 
driving arthritis development [9,10]. Our laboratory and others have used the mouse 
model system to elucidate key regulators of host immune response to infection. 
Since its discovery, nuclear factor-kappa B (NF-κB) has been identified as a key 
regulator in many cellular functions, including inflammation and cancer	  [11]. B. 
burgdorferi lipoproteins are extremely potent activators of Toll-like receptor 2 (TLR2)-
mediated NF-κB activation and cytokine production, and are important for host defense 
[12-16]. Mice lacking TLR2 or the adapter protein myeloid differentiation primary 
response gene (88) (MyD88) exhibit a failure to control infection [14,17-21]. Although 
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these knockout studies clearly demonstrate an important role of NF-κB in host defense, 
elucidating its role in inflammation and Lyme arthritis has remained elusive. 
While NF-κB activation is critical in response to infection, downregulation is 
equally important to avoid excess inflammation, tissue damage, and autoimmunity [22]. 
MicroRNAs (miRNAs) have recently been identified as being important regulators of 
NF-κB [23] and autoimmunity [24]. These small regulatory RNAs are posttranscriptional 
regulators of gene expression [25], and one miRNA, miR-146a, has been shown to be a 
modulator of innate immune response to Toll-like receptor (TLR) ligands [26]. Targets of 
miR-146a include TNF receptor associated factor 6 (TRAF6) and IL-1 receptor 
associated kinase 1 (IRAK1), adaptor molecules downstream of the MyD88-dependent 
TLR and cytokine signaling pathways [27]. Importantly, miR-146a itself is upregulated 
by IL-1β and TLRs, including TLR2, and thus acts as a negative feedback regulator of 
NF-κB signaling, which is required for immune homeostasis in vivo [27-31]. 
Aberrant microRNA expression, particularly miR-146a, has been associated with 
a variety of inflammatory disorders [32]. In systemic lupus erythematosus, a functional 
variant in the miR-146a promoter is associated with disease risk [33], and abnormally 
low miR-146a expression has been associated with more severe symptoms [34]. In 
contrast, rheumatoid arthritis synovial fibroblasts express abnormally high levels of miR-
146a [35,36], while osteoarthritis chondrocytes express variable levels miR-146a, 
correlating with disease severity [37,38]. 
Despite correlative evidence linking aberrant miRNA expression to diseases such 
as lupus, RA, and OA, determining whether miRNAs play an active role in pathogenesis 
has yet to be elucidated, and to our knowledge, no studies have examined the role of 
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miRNAs in Lyme arthritis. For these reasons, we sought to determine whether changes in 
miRNA expression contributed to host defense and Lyme arthritis development during B. 




miR-146a is highly upregulated in B6, C3H, and B6 IL10-/-  
mice during infection 
 MicroRNA dysregulation has been associated with a number of inflammatory 
disorders, and we hypothesized that these may play an important role in response to B. 
burgdorferi infection and Lyme arthritis development. We therefore performed a 
genome-wide screen of changes in miRNA expression in joints of B6, C3H, and B6 IL-
10-/- mice infected with B. burgdorferi at one and two weeks postinfection using an 
Agilent mouse microRNA microarray (Table 3.1, Table 3.S1). MicroRNAs differentially 
regulated included many that have been identified previously as important regulators of 
immune function. Interestingly, each infection model had a unique miRNA expression 
“signature,” and we found that only a few dozen miRNAs showed changes in expression 
during infection. Most of these changes were in C3H mice, and may be due to both 
differences in inflammatory response and intrinsic differences in miRNA function 
between strains. At two weeks postinfection, two miRNAs, miR-21 and miR-146a, both 
induced by NF-κB and associated with TLR signaling, were the most highly upregulated 
in all three strains (Table 3.1), and were confirmed using qRT-PCR (Figure 3.1). 
Furthermore, these miRNAs maintained high expression, even at 4 weeks postinfection. 
Interestingly, miR-155 was significantly upregulated in B6 IL10-/- mice, but not in B6 or 
C3H mice. This microRNA is a proinflammatory NF-κB-induced miRNA associated 
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with T cell-dependent inflammation and autoimmunity [39-41], and expression is 
suppressed by IL-10 [42].  
Of these, miR-146a was of particular interest, given recent reports showing a link 
between miR-146a and susceptibility to a variety of inflammatory disorders. Targets of 
miR-146a, IRAK1 and TRAF6 [27], are involved in TLR2/NF-κB activation, which is an 
important pathway in controlling B. burgdorferi infection [13,14,17-21]. Also, the 
observation that miR-146a was upregulated in all three strains suggested that this miRNA 
likely plays a general role in regulating the immune response to B. burgdorferi. For these 
reasons, our focus turned to studying miR-146a. A B6 miR-146a-/- knockout mouse was 
recently generated [28], which provided a powerful tool to evaluate the role of miR-146a 
in mildly arthritic B6 mice. While miR-146a was also upregulated in arthritis-susceptible 
C3H mice, we suspected that other genetic factors play a dominant role in arthritis 
development, including excessive Type I IFN production [43,44] and accumulation of 
undigested glycosaminoglycans in joint tissue [45]. These effects may limit the ability of 
miR-146a to modulate arthritis development in the C3H mouse model. It is tempting to 
speculate, however, that lack of miR-146a in the arthritis-susceptible C3H mouse would 




Impact of miR-146a on Lyme arthritis, carditis, and host defense 
Since miR-146a is an important negative regulator of NF-κB activation, we 
hypothesized that a B6 mouse deficient in miR-146a would develop more severe arthritis 
during infection with B. burgdorferi compared to WT controls. To avoid age-related 
pathologies associated with B6 miR-146a-/- mice [30], we used 6-8 week-old mice, which 
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is also the age of optimal arthritis in other mouse strains. Arthritis was assessed in B. 
burgdorferi-infected B6 and B6 miR-146a-/- mice. At 4 weeks postinfection, B6 miR-
146a-/- mice developed significantly more severe arthritis. Several markers of arthritis 
were elevated in B6 miR-146a-/- mice, including ankle swelling (Figure 3.2A), number 
and severity of lesions observed, polymorphonuclear (PMN) cell infiltrate, 
reactive/reparative score (periosteal hyperplasia and new bone formation and 
remodeling), and tendon sheath thickness (Table 3.2). Cranial tibial tendon is enlarged in 
Figure 3.2B. Control (BSK-injected) mice showed no significant arthritis in either strain, 
and no significant difference between strains was seen in mononuclear cell infiltrate into 
inflammatory processes. Importantly, B6 miR-146a-/- mice did not display overwhelming 
numbers of bacteria; rather, they tended to have somewhat fewer bacteria in infected 
joints and similar burden in infected heart and ear tissue, as measured by B. burgdorferi-
specific16S rRNA normalized to β-actin in joints and heart, and recA normalized to 
mouse nidogen in ear tissue (Figure 3.2C). This difference in bacterial load in joint tissue 
was likely not due to differences in antibody response since B. burgdorferi-specific IgM 
and IgG levels were similar between the two strains at 2 weeks and 4 weeks 
postinfection, respectively (Figure 3.2D). While this does not rule out the possibility that 
different borrelial proteins could be opsonic targets in the two strains, these data support 
the notion that increased arthritis observed in B6 miR-146a-/- mice was likely due to a 
defect in regulation of host immune function rather than compromised host defense. In 
fact, the decrease in 16S rRNA in B6 miR-146a-/- mouse joints indicated that arthritis 
development was independent of bacterial density. This increased arthritis severity with 
accompanying decreases in bacterial burden is also observed in the B6 IL10-/- mouse 
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model of arthritis [9,47,48], and is believed to be due primarily to enhanced innate 
immune responses [49]. 
In addition to joints, the heart is another target of B. burgdorferi infection in mice. 
We therefore looked for evidence of miR-146a modulating inflammation in heart tissue. 
Mice are susceptible to Lyme carditis in an MHC-independent manner, and exhibit 
variation in disease severity, with C3H mice harboring a greater number of bacteria and 
developing more severe carditis and B6 mice being resistant and harboring fewer bacteria 
[7,50,51]. Lyme carditis is also observed in humans, and although rare, can be fatal [52]. 
To assess the role of miR-146a in modulating heart inflammation, B6, B6 miR-146a-/-, 
and C3H mice were infected with B. burgdorferi for 3 weeks and hearts were removed 
and assessed for bacterial numbers and changes in transcripts of inflammatory genes. As 
was seen at 4 weeks postinfection (Figure 3.2C), bacterial burden, as measured by qRT-
PCR analysis of B. burgdorferi 16S rRNA, was similar between B6 and B6 miR-146a-/- 
mice, and both trended lower than what was seen in heart tissue from C3H mice (Figure 
3.3A). Lesions in the heart were also scored for carditis in B6, B6 miR-146a-/-, and C3H 
mice at 3 weeks postinfection. Overall lesion scores were similar in B6 and B6 miR-
146a-/- mice, and both trended lower than lesion severity in C3H mice (Figure 3.3B).  
Lesions in hearts at 3 weeks postinfection were characterized by acute to subacute 
vasculitis/perivasculitis (see Figure 3.3C) of the 1) microvasculature (capillaries) at the 
base of the heart (in heart muscle) where the aorta and pulmonary arteries arise, 2) 
microvasculature (capillaries) within connective tissues supporting these arteries, and 3) 
microvasculature (capillaries) of the vasa vasorum of the aorta and pulmonary arteries. 
These lesions affected the vascular system, rather than being primary lesions of the heart 
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muscle (myocarditis). The character and pattern of distribution of these lesions suggested 
that inflammation of the microvasculature is the result of some type of localized target 
cell (i.e., endothelium) or target substance (i.e., bacteria) specificity for this location 
consistent with Borrelial adhesin-host ligand binding within the vascular endothelium 
[53,54]. Vascular turbulence or oxygen concentration could also be involved. 
Lyme carditis is associated with macrophage infiltration [50], and invariant NKT 
cells have been shown to play a protective role in B6 mice [55]. We therefore used PCR 
analysis of macrophage (CD11b and F4/80) and NKT cell (CD4 and Vα14) markers to 
assess changes in cellularity in infected heart tissue (Figure 3.3D), as performed 
previously [56,57]. Significant upregulation of macrophage markers CD11b and F4/80 
was observed in all three strains, as expected based on previous research [50]. The 
magnitude of upregulation was not different between B6 and miR-146a deficient mice, 
indicating no role of miR-146a feedback on inflammation in this tissue. Interestingly, 
while CD11b and F4/80 transcripts were also significantly upregulated in C3H mice, the 
degree of upregulation was somewhat less than upregulation observed in B6 and B6 miR-
146a-/- mice at 3 weeks postinfection. Because these data are from whole heart tissue, 
they reflect cumulative changes in myeloid cell numbers from the entire heart, including 
changes in resident cardiac macrophages [58], which may dilute out lesion-specific 
changes identified by histopathology.  
CD4 transcript levels were not significantly different between strains, but while 
both B6 and B6 miR-146a-/- mice contained similar levels of Vα14 that trended higher at 
3 weeks, C3H mice had very low levels of this transcript in both uninfected and infected 
heart tissue. This is consistent with significant variation of NKT cell numbers between 
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different mouse strains [57]. PCR analysis was also used to determine changes in 
expression of various inflammatory cytokines and chemokines in heart tissue (Figure 
3.3D). As previously reported, C3H mice had elevated levels of IFNγ transcripts in 
infected heart tissue [59], which was significantly higher than IFNγ mRNA in B6 and B6 
miR-146a-/- hearts. This trend was also observed for IL6 transcripts, although there was 
significant variation in expression within C3H mice. No differences among B6, B6 miR-
146a-/-, and C3H mice were observed for transcripts of IL1β, TNFα, Cxcl1, Cxcl2, Ccl2, 
IL10, or IL12 (data not shown). Together, these data suggest that the nature of host 
defense, macrophage and NKT cell proliferation and infiltration, as well as cytokine and 
chemokine expression, is very similar in infected B6 and B6 miR-146a-/- heart tissue, but 
is quite distinct from observations in carditis-susceptible C3H mice. Fundamental 
differences between strains have been reported previously in Lyme carditis studies 
comparing the effect of Stat1 [60] and Ccr2 [51] deficiencies on carditis-susceptible and 
carditis-resistant mouse strains. Together, these data show that while strain-specific 
variables influence differences in carditis susceptibility between B6 and C3H mice, miR- 
146a has no impact on carditis severity in B6 mice. 
 
 
B6 miR-146a-/- mice exhibit hyperactive expression of NF-κB 
target cytokines and chemokines at 4 weeks postinfection 
Because miR-146a is known to negatively regulate NF-κB activation, we 
compared transcripts of genes upregulated by NF-κB in infected joint tissue from B6 and 
B6 miR-146a-/- mice at 2 and 4 weeks postinfection. We observed that a number of NF-
κB inducible genes were significantly elevated at 4 weeks postinfection (but not at 2 
weeks), by qRT-PCR, in B6 miR-146a-/- joints, compared to WT, including cytokines IL-
	   53	  
	  
1β and IL-6, as well as neutrophil chemokines Cxcl1 and Cxcl2 (Figure 3.4A). CXCL1 
has been shown to be required for full arthritis development in C3H mice [61,62], and 
increased expression of this gene in B6 miR-146a-/- mice could be directly contributing to 
arthritis development through recruitment of neutrophils. This is supported by the 
increase in PMN infiltrate seen at 4 weeks by histopathology, shown in Table 3.2. 
Elevated IL-1β transcript level is also particularly interesting, since the IL-1 receptor (IL-
1R) uses the same adaptors as TLR2/1 for signal transduction, is strongly upregulated by 
myeloid cells during phagocytosis of B. burgdorferi [63], and is dependent on IRAK1 
and TRAF6, two miR-146a targets [27]. Furthermore, IL-1β stimulates miR-146a 
upregulation in vitro [27], suggesting that this miRNA negatively regulates IL-1β 
signaling. It is important to note that uninfected B6 miR-146a-/- mice did not exhibit any 
abnormalities in expression of these genes, indicating that this hyperactivity is due to a 
failure to downregulate the NF-κB response after infection, rather than general NF-κB 
hyperactivity, as is observed in aging B6 miR-146a-/- mice [30].  
Only a distinct subset of inflammatory cytokines and chemokines (IL-1β, IL-6, 
Cxcl1, Cxcl2) appeared to be dysregulated in B6 miR-146a-/- joints. Transcript levels of 
other Lyme arthritis-associated genes (IFNγ, Cxcl10, TNFα) were very similar between 
the two strains (Figure 3.4A), and showed a peak in expression at 2 weeks postinfection, 
followed by resolution at 4 weeks. This is in contrast to arthritis-susceptible B6 IL10-/- 
mice, where previously published data show that in addition to upregulation in IL-1β, IL-
6, Cxcl1, Cxcl2, IFNγ, and Cxcl10 are upregulated 16-fold and 141-fold at 2 weeks, and 
22-fold and 189-fold at 4 weeks, respectively [47]. These data together indicate that the 
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B6 miR-146a-/- mouse is distinct from the B6 IL10-/- model, which is associated with a 
dramatic IFNγ signature in joints and elevation of IFNγ in serum at 4 weeks p.i. [47,48]. 
In order to determine whether there was systemic dysregulation of NF-κB-
inducible cytokines, serum was collected from B. burgdorferi-infected mice at 4 weeks 
postinfection and cytokine levels were measured by enzyme-linked immunosorbent assay 
(Figure 3.4B). B6 miR-146a-/- mice contained higher levels of IL-6 at 4 weeks 
postinfection, compared to wild-type, consistent with observations in joint tissue. TNFα 
and IL-12 serum levels were very similar between strains, and although levels of IFNγ  
varied widely in B6 miR-146a-/- mice, they were not significantly greater than B6 levels.  
 
 
Effect of miR-146a in cell populations isolated from joints early  
in infection  
To identify the effect of miR-146a in various joint cell populations during the 
early phage of infection ex vivo, we digested joints with purified collagenase to release 
cells into a single-cell solution in order to identify and isolate cell fractions based on 
lineage markers, including CD45 for leukocytes, CD11b for myeloid cells, CD31 for 
endothelial cells, and CD29 for fibroblast-enriched cells (Figure 3.5A). This method has 
been used in C3H mice to identify cellular sources of genes associated with the 
arthritogenic Type I IFN response early in infection, and is a sensitive assay to observe 
cell type-specific effects ex vivo that might be missed using whole joint tissue [43]. Using 
this method, we were able to determine the effect of miR-146a on specific cell types early 
in infection (Figure 3.5B). Levels of IL-1β, while trending higher in myeloid cells 
isolated from B6 miR-146a-/- mice, were not significantly different between the two 
strains. In B6 mice, three genes, Cxcl2 and the IFN-inducible gene Oasl2 (in myeloid 
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cells) and Cxcl1 (in fibroblasts), tended to peak in expression at Day 7 postinfection. In 
contrast, transcripts were somewhat higher in uninfected B6 miR-146a-/- cell fractions vs. 
WT, and remained elevated throughout infection. This suggests that B6 miR-146a-/- mice 
may be poised to initiate a hyperactive immune response. There was no difference in 
lymphoid IFNγ expression between strains, which peaked at Day 14 postinfection, as was 
seen in whole joint tissue (Figure 3.4A). It is important to note that, unlike published 
observations in C3H mice [43], B6 miR-146a-/- mice did not exhibit a robust induction of 
IFN-responsive genes, such as Oasl2, in fibroblasts or endothelial cells at Day 7 
postinfection (data not shown). Overall, these data, combined with data from Figure 3.4, 
suggest that a number of NF-κB-inducible genes in B6 miR-146a-/- mouse joints are 
poised for hyper-activation prior to infection, and peak at 4 weeks postinfection, 
indicating that miR-146a acts to resolve the inflammatory response late in infection,  
rather than limiting the amplitude of inflammation during early stages of infection.  
 
 
Myeloid cell recruitment is increased in infected joints of B6  
miR-146a-/- mice 
During cell sorting, we observed differences in cellular infiltrate, particularly in 
the myeloid cell lineages, in joints during infection. Therefore, a more rigorous analysis 
of myeloid cells recruited to the joint by flow cytometry was performed at various times 
during infection. Using joint cell isolation methods described in Figure 3.5, myeloid cells 
were characterized from infected joints at 2 and 4 weeks postinfection using fluorescently 
labeled antibodies against CD11b, F4/80, Ly6C, Gr1, and CD206. CD11b+ myeloid cell 
populations clustered roughly into three populations, F4/80+ Ly6Clo macrophages, Gr1hi 
Ly6Cint PMNs, and Gr1int Ly6Chi monocytes (Figure 3.6A&B). Furthermore, F4/80+ 
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Ly6Clo macrophages expressed variable levels of CD206 (MRC1, Mannose Receptor C 
type 1), a marker of alternatively activated (M2-like) macrophages [64]. There was little 
difference between strains in mean fluorescence intensity (MFI) of MRC1 and Gr1 in 
each myeloid subpopulation, suggesting that they were phenotypically similar 
populations. However, while the number of these three myeloid populations in B6 mouse 
joints changed only modestly in B6 mice, myeloid cell numbers in B6 miR-146a-/- joints 
were significantly elevated at both 2 and 4 weeks postinfection (Figure 3.6C). An 
increased trend in PMN infiltration in B6 miR-146a-/- mice is also consistent with 
histopathology data shown in Table 3.2, despite the propensity of PMNs to lyse during 
enzymatic digestion of joint tissue, resulting in some sample to sample variation. 
Interestingly, there was little difference between strains in infiltrating lymphoid cells at 2 
or 4 weeks postinfection (Figure 3.S1). These data, as well as the observation of similar 
B. burgdorferi-specific antibody levels (Figure 3.2D), suggest that arthritis and host 
defense phenotypes observed in B6 miR-146a-/- mice shown in Figure 3.2 and Table 3.2  
are driven primarily by myeloid cells. 
 
 
Bone marrow-derived macrophages from B6 miR-146a-/- mice are 
hyper-responsive to B. burgdorferi and have elevated protein 
levels of TRAF6 
 The data from Figure 3.6 implicated myeloid cells as contributors of arthritis 
development in B6 miR-146a-/- mice. We therefore turned to bone marrow-derived 
macrophages (BMDMs) to elucidate the molecular mechanism of miR-146a regulation of 
NF-κB during B. burgdorferi infection. BMDMs were cultured from bone marrow 
extracted from B6 or B6 miR-146a-/- mice and treated with B. burgdorferi for 6 and 24 
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hours. We then measured transcripts of IL1β, IL6, and TNFα (Table 3.3). Transcripts of 
IL1β were approximately 4-fold higher in B6 miR-146a-/- BMDMs, vs. WT, at both 6 and 
24 hours, and IL6 levels were 7.5-fold higher at 6 hours and 2.5-fold higher at 24 hours 
poststimulation. Interestingly, TNFα transcripts were only 20-30 percent higher in B6 
miR-146a-/- BMDMs, compared to WT. Transcripts for all three cytokines were very low 
in uninfected cells, and were similar between the two strains (data not shown). This 
suggests that miR-146a effect on IL1β and IL6 regulation is greater than its effect on 
TNFα expression. 
We also measured levels of several NF-κB inducible cytokines by ELISA in cell 
supernatant from both B6 and B6 miR-146a-/- BMDMs at 24 hours poststimulation, 
including TNFα IL-1β, IL-6 and IL-12, CXCL1, and IL-10 (Figure 3.7A). After 24 hours 
of treatment with B. burgdorferi, three cytokines, IL-1β, IL-6, and IL-12, and the 
neutrophil chemokine CXCL1, were more abundant in B6 miR-146a-/- cell supernatant 
than in B6 cell supernatant, consistent with hyperactive NF-κB activation and transcript 
analysis (Table 3.3). Interestingly, TNFα, an early-response NF-κB cytokine, did not 
share this trend, which may be due to the relatively late time point used for this analysis 
[65]. Production of IL-10 was robust in both strains, although somewhat greater in miR-
146a-deficient BMDMs.  
Previous work from our laboratory showed that many macrophages are IL-10 
producers in joints of B6 mice [48]. Also, macrophages produce high levels of IL-10 
when treated with B. burgdorferi in vitro, which is important in regulating bacterial 
persistence [49] and immune response [46,66-68]. Data from Figure 3.6B also showed 
that many macrophages in joints of infected B6 and B6 miR-146a-/- mice express the 
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alternatively activated macrophage marker MRC1. While it is difficult to accurately 
determine the range of macrophage phenotypes present in joints, we used BMDMs 
pretreated with IL-10 as an in vitro model to study miR-146a effects on IL-10-stimulated 
macrophages. BMDMs were treated with 1ng/ml IL-10 for 4 hours prior to 24-hour B. 
burgdorferi stimulation. Surprisingly, while pretreatment with IL-10 led to an 
approximately 80 percent reduction in IL-6 production in B6 BMDMs, IL-10-mediated 
suppression of IL-6 in B6 miR-146a-/- BMDMs was drastically reduced, with only ~20 
percent decrease in IL-6 production after IL-10 pretreatment, indicating that IL-10 was 
unable to effectively suppress IL-6 expression in the absence of miR-146a. These data are 
consistent with in vivo data showing consistently elevated IL-6 protein in serum from 4 
week-infected B6 miR-146a-/- mice in Figure 3.4. However, IL-10 pretreatment did lead 
to significantly reduced IL-12 and TNFα production in both strains, as well as high 
production of IL-10, after B. burgdorferi treatment, consistent with an anti-inflammatory 
M2-like phenotype. Both IL-1β and CXCL1 remained higher in B6 miR-146a-/- BMDMs 
compared to B6 BMDMs, although IL-1β levels were unaffected, and CXCL1 levels 
were modestly reduced by IL-10 pretreatment. Importantly, levels of IL-12, TNFα, and 
IL-10 were very similar between the two strains, suggesting there was no miR-146a-
mediated defect in M2 polarization in response to IL-10 pretreatment. This is consistent 
with in vivo observations, where TNFα, IL-12, and IFNγ serum protein levels were not 
significantly elevated in B6 miR-146a-/- mice at 4 weeks postinfection, relative to B6 
mice (Figure 3.4B). 
 MicroRNAs, including miR-146a, have distinct mRNA targets, depending on cell 
type [69]. It was therefore important to determine the mRNA target most affected at the 
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protein level by the presence or absence of miR-146a in BMDMs. Immunoblot analysis 
was performed on protein extracts from B6 and B6 miR-146a-/- BMDMs treated for 24 
hours with B. burgdorferi to measure protein levels of three targets of miR-146a, TRAF6, 
IRAK1, and STAT1 (Figure 3.7B). TRAF6 protein expression was elevated over 2-fold 
in both resting and stimulated B6 miR-146a-/- BMDMs compared to B6, while protein 
levels of IRAK1 were similar between strains. STAT1 protein was also higher in resting 
B6 miR-146a-/- BMDMs compared to B6, but this difference between strains was not 
observed after 24 hours stimulation. Transcript analysis of Traf6, Irak1 and Stat1 also 
show this trend (Figure 3.7C). It is interesting that in the case of TRAF6, the difference 
observed at the protein level was greater than that seen at the transcript level, where 
transcripts were typically only 30-50 percent greater in B6 miR-146a-/- BMDMs vs. B6 
BMDMs, suggesting that miR-146a effect on translational inhibition is more pronounced 
than its effect on mRNA stability. This is consistent with a growing body of evidence 
suggesting that microRNA-mediated translational repression is dependent on inhibition 
of translation initiation, rather than mRNA degradation [70,71]. The difference between 
protein and transcript levels of these three genes (Figure 3.7B, C) strongly suggests that 
posttranscriptional regulatory mechanisms including, but not limited to, microRNA-
mediated repression, play an important role in determining cellular protein levels. STAT1 
is known to be regulated by a large number of posttranslational modifications that affect 
function [72]. Both STAT1 and IRAK1 protein levels have been shown to be tightly 
regulated through ubiquitin E3 ligase-directed degradation [73,74]. In the case of IRAK1 
and STAT1, these data suggest that miR-146a-independent regulatory mechanisms seem 
to be dominant compared to miR-146a-mediated regulation. Taken together, TRAF6 
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protein levels appear to be the most sensitive to the presence or absence of miR-146a in 
myeloid cells, and imply miR-146a-mediated translational repression of TRAF6 is 
required to properly regulate production of NF-κB-induced cytokines in response to B. 
burgdorferi. The lack of difference in STAT1 protein level is also consistent with a 
failure to observe significant differences between B6 and B6 miR-146a-/- mice in the IFN  
response (Figures 3.4&3.5). 
 
 
Macrophages lacking miR-146a have increased phagocytic activity 
 One possible explanation for reduced numbers of B. burgdorferi in joints of 
infected B6 miR-146a-/- mice is that macrophages lacking miR-146a are more highly 
phagocytic. In order to measure phagocytic activity, peritoneal macrophages were 
collected from B6 and B6 mir-146a-/- mice and stimulated with GFP-labeled B. 
burgdorferi for 1 or 2 hours at 10:1 MOI. Phagocytosis of GFP-B. burgdorferi was 
measured by flow cytometry (Figure 3.8A&B). At both 1 and 2 hours poststimulation, 
peritoneal macrophages lacking miR-146a had significantly higher numbers of GFP+ 
cells, as well as a higher MFI for GFP in GFP+ macrophages. These data suggest that 
there are more B6 miR-146a-/- peritoneal macrophages associated with higher numbers of 
bacteria than WT cells. 
 Flow cytometry was unable to distinguish localization of the cell-associated 
bacteria. To determine whether GFP-B. burgdorferi were intracellular or adhering to the 
cell surface, confocal microscopy was used to visualize the bacteria associated with 
peritoneal macrophages. Peritoneal macrophages were stimulated with GFP-B. 
burgdorferi at 100:1 MOI for 1 hour and stained for the lysosomal protein LAMP1 (red), 
the macrophage-specific surface protein F4/80 (blue), and nuclei were stained with DAPI 
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(gray, Figure 3.8C). Bacteria were visible adhering to cell surface (white triangle), inside 
macrophage pseudopodia (white arrow) and inside cells associated with LAMP1 (white 
chevron). While bacteria adhering to the cell surface and inside pseudopodia had a 
spirochetal shape, bacteria associated with lysosomes were amorphous, and formed bright 
GFP puncta, indicative of bacterial degradation. These bright GFP puncta were 
predominant throughout the entire sample, as represented in the image in Figure 3.8C for 
B6 mice, and in Figure 3.S2 for B6 miR-146a-/- mice. This indicates that phagocytosis 
occurs very rapidly as previously reported [65], and the flow cytometry analysis infers 
that miR-146a modulates the level of phagocytic activity. Although the mechanism is 
unknown, similar transcript levels were seen for TLR2, CD14, as well as the scavenger 
receptor MARCO (data not shown), which have been recently implicated in B. 
burgdorferi uptake [75-78]. Previous reports showing phagocytosis influencing cytokine 
production in human mononuclear cells [78], and B6 MyD88-/- BMDMs being defective 
in bacterial internalization [79], are consistent with B6 miR-146a-/- BMDMs having 
elevated cytokine production and enhanced phagocytic activity (Figure 3.7, Table 3.3, 
Figure 3.8). While more research is necessary to elucidate this mechanism, these data 
suggest that B6 miR-146a-/- macrophages have enhanced phagocytosis, and may help 





 These data have allowed us to generate a model (Figure 3.9) where miR-146a is 
upregulated during B. burgdorferi infection, and acts as a nonredundant suppressor of 
inflammation and arthritis (Figures 3.1&3.2). Interestingly, lack of miR-146a had no 
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effect on heart inflammation and carditis (Figure 3.3), indicating fundamental differences 
between arthritis and carditis development. Differences in carditis severity between B6 
and C3H mice are believed to be closely associated with differences in bacterial 
dissemination and clearance between the two strains [80]. This is consistent with the 
positive correlation between bacterial numbers and heart lesion severity in B6, B6 miR-
146a-/-, and C3H mice (Figure 3.3A-B), and with previous reports showing no correlation 
between quantitative trait loci associated with arthritis severity and bacterial numbers in 
heart tissue [81,82]. Importantly, differential contribution of NF-κB regulation was not 
predicted from studies with mice deficient in TLR2 and MyD88, as both hearts and joint 
tissues displayed increased presence of B. burgdorferi [18,19,83].  
Numerous studies have revealed different mechanisms of pathogenesis in carditis 
development and differing contributions of innate and adaptive responses in bacterial 
clearance and resolution of carditis and arthritis. For example, although antibody 
response plays an essential role in resolution of arthritis, a greater role for CD4+ T cells 
and iNKT cells as sources of IFNγ are reported in protection and resolution of Lyme 
carditis [55,60,84-86]. Other gene knockout and cytokine blocking studies have shown 
tissue-specific effects of IL-10 [46] and chemokines [51,62] on arthritis and carditis 
severity. These results suggest future microRNA studies on carditis should focus on those 
miRs known to influence the balance of CD4+ T cells [87] and iNKT cell function, such 
as miR-150 and miR-181a/b [88-90].  
Myeloid cells respond to a variety of Borrelia stimuli through TLRs that lead to 
activation of NF-κB and upregulation of hundreds of genes involved in controlling 
infection and initiating the adaptive response. miR-146a is also upregulated, and is an 
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important check on the amplitude and duration of the NF-κB response. In the absence of 
this microRNA, this response is dysregulated, leading to increased transcription of certain 
NF-κB-inducible cytokines and chemokines in infected joint tissue, primarily late in 
infection (Figures 3.4&3.5). Myeloid cells exhibit excessive proliferation and infiltration 
into joint tissue of B6 miR-146a-/- mice, have increased phagocytic activity, and produce 
excess cytokines such as IL-1β, IL-6, and CXCL1, leading to inflammation of synovial 
tissue and arthritis development (Figures 3.6-3.8). Regulation of the inflammatory 
response via a miR-146a-mediated negative feedback loop is critical for resolution of the 
NF-κB response during the persistent phase of infection, and mice lacking this miRNA 
are poised to develop arthritis upon infection with B. burgdorferi.  
 NF-κB activation in response to B. burgdorferi infection is a double-edged sword. 
On one hand, NF-κB activation is critical in mounting an effective immune response to 
control infection; on the other hand, dysregulated activation leads to inflammation and 
arthritis. Because of the dual nature of NF-κB in inflammation and host defense, 
decoupling these two roles has been difficult. Knockout models using B6 TLR2-/- or 
MyD88-/- mice have shown the important role of NF-κB in host defense, but because 
these mice have such a severe innate defect in bacterial defense, elucidating the role of 
NF-κB in arthritis using these models has remained difficult. The B6 miR-146a-/- mouse 
model of Lyme arthritis is unique in that it effectively decouples these two roles, leaving 
the bactericidal function intact while increasing the amplitude of proinflammatory NF-κB 
activation. This has allowed us to identify its role in arthritis development, independent 
of its role in host defense, and suggests that miR-146a could be a valuable therapeutic 
target for control of inflammation without compromising ability to clear an infection. 
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 MicroRNAs are a unique class of regulatory molecules. Unlike transcription 
factors, they do not act as on/off switches; rather they function as “fine tuners” of gene 
expression [26]. We have taken advantage of this property to decouple the roles of NF-
κB in host defense and inflammation. Young B6 miR-146a-/- mice are phenotypically 
similar to wild-type B6 mice, and it is only upon chronic exposure to inflammatory 
stimuli that immunological defects are seen [29]. Consistent with this, endotoxin 
tolerance is highly dependent upon miR-146a expression in THP-1 cells [91]. Using 
Lyme arthritis as a model, we have shown that mice lacking this key miRNA fail to 
adequately maintain immune homeostasis, and develop inflammatory arthritis during a 
chronic bacterial infection (Figure 3.2, Table 3.2).  
 This model is also distinct from other mouse models of Lyme arthritis. For 
example, C3H mice exhibit a robust Type I IFN expression profile early in infection, 
which contributes to arthritis, and is absent in the mildly arthritic B6 mouse [43,44,47]. 
This IFN response was also absent miR-146a-/- mice, similar to B6. Furthermore, B6 
IL10-/- mice, a model for Th1-mediated arthritis, have a very pronounced IFNγ signature 
beginning at 14 days postinfection that persists for several weeks [48]. This pattern was 
also not observed in the arthritic B6 miR-146a-/- mice (Figures 3.4&3.5, Figure 3.S1). 
Additionally, while B6 miR-146a-/- and B6 IL10-/- mice both exhibit increased bacterial 
clearance, likely due to an enhanced myeloid response to phagocytosis of bacteria [63], 
only B6 IL10-/- mice show enhanced antibody response [49]. It was somewhat surprising 
that B6 miR-146a-/- mice did not exhibit a strong T-cell-mediated phenotype, based on 
parameters tested, since other studies have shown an important role of miR-146a in 
regulating Th1 responses [31,92]. It is possible that the elevated myeloid response could 
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eventually lead to a dysregulated T-cell response in some cases. Indeed, several B6 miR-
146a-/- mice did have elevated serum IFNγ at 4 weeks postinfection, although this was the 
exception rather than the rule, and average levels did not achieve statistical significance 
compared to wild-type mice (Figure 3.4C). It may also be possible that robust production 
of IL-10 seen in B6 miR-146a-/- mice is sufficient to suppress any T-cell dysregulation 
due to lack of miR-146a. Nevertheless, the results of this study show that arthritis is 
influenced principally by hyperactive myeloid cell activation.  
The role of miR-146a in regulating NF-κB activation was consistent with the 
observed defect in downregulation of NF-κB-dependent cytokines and chemokines IL-
1β, IL-6, Cxcl1, and Cxcl2, in B6 miR-146a-/- mice at 4 weeks postinfection (Figure 3.4). 
Dysregulation of Cxcl1 in these mice was particularly interesting because previous 
studies have shown that C3H mice lacking CXCL1 have reduced neutrophil infiltration 
and arthritis [61,62]. This neutrophil chemokine is tightly regulated both at the 
transcriptional and posttranscriptional level by both TLR-dependent and cytokine-
dependent mechanisms [93]. Data from Figure 3.7 suggest that excess cytokine 
production by B6 miR-146a-/- macrophages may lead to enhanced CXCL1 production by 
resident cells in vivo. Therefore, miR-146a, expressed primarily in leukocytes [29], likely 
has cell-extrinsic effects on nonhematopoietic cell function and arthritis development. 
Recently, IL-6 has been shown to be an important downstream target of miR-146a in 
regulating hematopoiesis and myeloproliferation [29]. This is consistent with increased 
IL-6 production shown in Figure 3.4 and Figure 3.7, and corresponding increase in 
myeloid cell infiltration into joint tissue (Figure 3.6). Thus, miR-146a-mediated 
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regulation of several cytokines and chemokines likely has a combined effect on 
inflammatory responses.  
Increased phagocytic activity, as well as elevated IL-1β production (Figures 
3.7&3.8), point to a previously unrecognized role of miR-146a in phagocytosis and 
caspase-1 activation. While this role remains to be elucidated, previous research has 
shown that B. burgdorferi induces caspase-1-dependent IL-1β production, and caspase-1 
is important for inflammatory cell influx into joint tissue [94]. Additionally, phagocytosis 
of live B. burgdorferi is a potent activator of IL-1 β in human PBMCs [95]. 
Targets of miR-146a have been studied in many cell types, and it is becoming 
increasingly evident that the modulatory effect of miR-146a is dependent on cell type and 
physiological condition. For example, STAT1 appears to be an important miR-146a 
target in regulatory T-cells [92], and IRAK1 and TRAF6 both appear to be important 
miR-146a targets in splenocytes [31] and in human monocytes [30]. This study highlights 
the particular role of miR-146a targeting TRAF6 in myeloid cells (Figure 3.7), indicating 
that miR-146a function is, to a certain degree, cell type-specific. Importantly, several 
observations in the B6 miR-146a-/- mouse model are recapitulated in Lyme disease 
patients. Joint fluid and synovial tissue from antibiotic-refractory Lyme arthritis patients 
contain higher levels of IL-6 and IL-1β, as well as Th1 cytokines and chemokines, 
compared with patients whose arthritis is resolved after antibiotic treatment, and IL-1β 
remains elevated in these treatment-refractory patients long after antibiotic therapy 
[96,97]. Thus, the B6 miR-146a-/- model of Lyme arthritis could be a useful tool in  
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Materials and Methods 
Ethics statement 
 Mice were housed in the University of Utah Comparative Medicine Center (Salt 
Lake City, UT), following strict adherence to the guidelines according to the National 
Institutes of Health for the care and use of laboratory animals, as described in the Guide 
for the Care and Use of Laboratory Animals, 8th Edition. Protocols conducted in this 
study were approved and carried out in accordance to the University of Utah Institutional 
Animal Care and Use Committee (Protocol Number 12-01005). Mouse experiments were 




Mice, bacterial cultures and infections, and assessment of arthritis  
severity 
C3H, C57BL/6, and B6.129P2-IL-10tm1Cgn/J (B6 IL-10-/-) mice were obtained 
from Jackson Laboratories. B6 miR-146a-/- KO mice on a pure C57BL/6 background 
were generated as described [28]. Mice were infected with 2x104 bacteria of B. 
burgdorferi strain N40 (provided by S. Barthold, University of California, Davis, CA) by 
intradermal injection into the skin of the back. Infection was confirmed in mice sacrificed 
before 14 d of infection by culturing bladder tissue in BSK II media containing 6 percent 
rabbit serum (Sigma-Aldrich), phosphamycin, and rifampicin. ELISA quantification of B. 
burgdorferi-specific IgM and IgG concentrations was used to confirm infection in mice 
sacrificed at and after 14 d of infection as described [17]. Ankle measurements were 
obtained using a metric caliper. Rear ankle joints were prepared for assessment of 
histopathology by removal of the skin and fixation of tissue in 10 percent neutral buffered 
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formalin. Decalcified joints were embedded in paraffin, sectioned at 3 µm, and stained 
with H&E. Each slide was scored from 0 to 5 for various aspects of disease, including 
polymorphonuclear leukocyte (PMN) and mononuclear cell (lymphocytes, monocytes, 
macrophages) infiltration into inflammatory processes, tendon sheath thickening 
(hypertrophy and hyperplasia of surface cells and/or underlying dense sheets of cells 
resembling immature fibroblasts, synoviocytes, and/or granulation tissue), 
reactive/reparative responses (periosteal hyperplasia and new bone formation and 
remodeling), and overall lesion (composite score based on all lesions observed in 6-8 
sections per joint), with 5 representing the most severe lesion, and 0 representing no 
lesion. Ankle measurements and arthritic lesions were assessed in coded samples. 
Hearts of B6, B6 miR-146a-/-, and C3H mice were assessed for carditis by 
histopathologic evaluation at 3 weeks postinfection. Hearts were fixed in 10 percent 
neutral buffered formalin, embedded in paraffin, sectioned at 3 µm, and stained with 
H&E. Lesion scoring was performed in a blinded fashion based on a composite of 11 
sections per sample, with a score of 5 representing the maximum lesion and 0  




Microarray analysis was performed with the assistance of the University of Utah 
Microarray and Bioinformatics core facilities. Whole joint RNA was purified from mouse 
joints (3-4 mice per sample group) using miRNeasy kit (Qiagen). RNA quality was 
determined using a Bioanalyzer 2100 and RNA 6000 Nano Chip (Agilent Technologies). 
Agilent Mouse miRNA microarray v2 (8x15k) was hybridized with Cyanine-3 labeled 
miRNA (using 100 ng total RNA) using the Agilent one-color GE hybridization and 
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wash kit. Slides were scanned in a G2505C Microarray Scanner at 2 um resolution 
(Agilent Technologies). TIF files generated from the scanned microarray image were 
analyzed in the Agilent Feature Extraction Software (v.10.5), which was used to calculate 
feature intensities, background measurements, and statistical analyses. Data sets for each 
biological sample were then filtered and log(2) transformed using an in-house java script, 
and were uploaded into Geospiza GeneSifter Analysis Edition (Perkin Elmer). Pair-wise 
analysis between groups was performed using a quality cutoff for both groups of 1, 
normalizing to median values, with a cutoff value of 2-fold change compared to  
uninfected controls.  
 
 
Isolation of DNA from ear tissue and quantification of B.  
burgdorferi 
 DNA was prepared from ear tissues frozen at the time of sacrifice. Tissue was 
incubated in 50 mM NaOH for 1 hour at 93°C and neutralized with 1M Tris (pH 8). 
Quantification of B. burgdorferi recA normalized to the mouse nidogen was performed  
using a Roche LC-480 using previously published primers [18]. 
 
 
Preparation of single-cell suspensions from mouse tissue 
 Single-cell suspensions were prepared as previously described [43]. Skin was 
removed from rear ankle joints and digested for 1 hour at 37°C in RPMI 1640 containing 
0.2 mg/ml purified enzyme blend for tissue dissociation (Roche) and 100 µg/ml DNase I 
(Sigma-Aldrich), following partial removal of tissue from bone using 20-gauge syringe 
needles.  Single cell suspension was filtered through a 100 µm cell strainer and red blood  
cells were lysed using ammonium-chloride-potassium (ACK) lysing buffer.  
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Isolation of RNA and quantitative RT-PCR 
 For all experiments examining expression in heart and joint tissue, RNA was 
purified from the heart or tibiotarsal joints with the skin removed. Tissue was 
immediately immersed in RNA stabilization solution (Qiagen) and stored at -80°C. Total 
RNA was recovered from homogenized tissue using the miRNeasy kit (Qiagen). For 
FACS-sorted cell populations, sorted cells were collected directly in flow tubes 
containing 0.5 ml RNA stabilization solution (Qiagen) and RNA was recovered using the 
miRNeasy kit (Qiagen). RNA from BMDMs was recovered using guanidium 
thiocyanate-phenol-chloroform extraction reagent (Invitrogen). RNA recovered from 
tissue and cells was reverse transcribed, and transcripts were quantified using a Roche 
LC-480 according to our previously described protocols [47]. For mature miRNA 
quantification, cDNA was synthesized using the mercury Locked Nucleic Acid Universal 
RT microRNA PCR, Polyadenylation and cDNA synthesis kit (Exiqon), and miR-146a, 
5S rRNA Locked Nucleic Acid primer sets were used (Exiqon) to quantify miRNA using 
a Roche LC-480. Other primer sequences used in this study were as follows: Itgam 
(CD11b) FWD (5’-CCTTCATCAACACAACCAGAGTGG-3’) REV (5’- 
CGAGGTGCTCCTAAAACCAAGC-3’), Irak1 FWD (5’-
TGTGCCGCTTCTACAAAGTG-3’) REV (5’-TGTGAACGAGGTCAGCTACG-3’) 
Traf6 FWD (5’-AAGCCTGCATCATCAAATCC-3’) REV (5’-
CTGGCACTTCTGGAAAGGAC-3’). Primer sequences for B. burgdorferi 16S rRNA, β-
actin, Il1β, Stat1, Tnfa, Oasl2 [47], Vα14, F4/80 [48] Il10, Ifng, Cxcl10, Il6 [44] Cxcl1,  
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Flow cytometry 
All flow cytometry data were analyzed using FlowJo (v.5) software. Sorting 
experiments were performed using a BD FACSAria II. All other FACS data were 
collected on a BD LSRII flow cytometer. 7-aminoactinomycin D (eBioscience) or DAPI 
(Invitrogen) was used in all experiments, and dead cells and cell doublets were excluded 
from analyses. All Abs used for flow cytometry were purchased from either BioLegend 
or eBioscience. Unconjugated Fc blocking Ab (clone 93; BioLegend) was included in all 
Ab-labeling experiments. Position of gates for sorting and analysis was based on analysis 
of appropriate isotype controls. Fluorochrome-conjugated Abs and isotype controls used 
in this study were as follows: APC/Cy7-conjugated anti-CD11b (M1/70) and anti-
CD45.2 (104); FITC-conjugated anti-CD8a (53-6.7), anti-CD11b (M1/70), and anti-Gr-1 
(RB6-8C5); PerCP/Cy5.5-conjugated anti-Ly6C (HK1.4), anti-CD4 (RM4-4), and anti-
CD31 (390); PE-conjugated anti-F4/80 (BM8), anti-LAMP-1 (1D4B), and anti-NK1.1 
(PK136); PE/Cy-7–conjugated anti-CD4 (GK1.5) and anti-TCR β (H57-597); APC-
conjugated anti-CD206 (MMR) and anti-F4/80 (BM8); and Brilliant Violet 605-
conjugated anti-B220 (RA3-6B2). Confirmation of cell sorting efficiency was performed  
using qRT-PCR of surface markers used. 
 
 
Bone marrow-derived macrophage stimulation 
Bone marrow-derived macrophages (BMDMs) were isolated from the femurs and 
tibias of mice, as previously described [98]. Macrophage cultures were plated in 12-well 
plates at a density of 6 × 105/ml in media containing the serum replacement Nutridoma 
(Roche) and stimulated with live B. burgdorferi cN40 (7.5 × 106/ml). Priming of 
macrophages was performed by preincubating cells with 1 ng/ml mouse recombinant IL-
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10 for 4 hours prior to addition of B. burgdorferi. After 24 hours, cell supernatants were 
collected and analyzed by enzyme-linked immunosorbent assay (ELISA). For expression 
analysis, RNA was collected from cells at 6 hours and 24 hours poststimulation, and  
mRNA quantification was performed by qRT-PCR using methods described above. 
 
 
ELISA analysis of mouse serum and cell supernatant 
 Blood from mice was obtained by submandibular puncture at the time of 
euthanasia. Blood was allowed to clot, centrifuged, and serum was collected and stored at 
-20°C prior to analysis. Cell supernatant was used immediately or stored at -20°C prior to 
analysis. Cytokine concentration in serum samples and cell supernatant was detected by 
sandwich ELISA using capture and biotinylated antibodies against mouse IL-1β (clones 
B122 and Poly5158, Biolegend), IL-6 (clones MP5-20F3 and MP5-32C11, BD 
Biosciences), IL-10 (clones JESS-2A5 and SXC-1, BD Biosciences), IL-12 (clones C15.6 
and C17.8, BD Biosciences), IFNγ (clones R46A2 and XMG1.2, BD Biosciences), TNFα 
(clones G281-2626 and MP6-XT3, BD Biosciences), and CXCL1 (clone 48415 and Cat  




 Cells were washed and lysed at 4° C. with NP-40 lysis buffer (0.5 percent NP-40) 
for 1 hour followed by boiling for 5 minutes in SDS sample buffer. Protein concentration 
was measured using a BCA protein assay (Thermo Scientific). Proteins were separated by 
polyacrylamide gel electrophoresis (PAGE) and transferred overnight at 4°C. onto an 
Immobilon-P membrane (Millipore). Membrane was blocked with 5% milk in TBST and 
stained with the following antibodies: rabbit anti-TRAF6 (clone H-274, Santa Cruz), 
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rabbit anti-IRAK1 (clone D51G7, Cell Signaling), rabbit anti-STAT1 (Cell Signaling 
#H9172S), and rabbit anti-β-actin (clone 13E5, Cell Signaling) as a loading control. 
Horseradish peroxidase-conjugated goat anti-rabbit IgG (BioRad) was used as a 
secondary antibody prior to incubation with enhanced chemoluminescent substrate 
(Thermo Scientific). Membrane was exposed to autoradiography film (GeneMate) and  




 Mice received an intraperitoneal (IP) injection of 3 ml of 3 percent thioglycollate 
4 days prior to harvesting of peritoneal macrophages. Macrophages were removed from 
sacrificed mice by IP injection of 5 ml ice-cold PBS. Red blood cells were lysed using 
ACK lysis buffer. 5x105 cells were adhered to a 12-well plate in RPMI+10 percent FBS 
for 4 hours, after which cells were washed and unadhered cells removed. 5x106 B. 
burgdorferi strain N40 constitutively expressing GFP under the flaB promoter [99] (a gift 
from Dr. Jay Carroll) were added to cells in RPMI.B (75 percent RPMI+10 percent 
FBS+25 percent BSKII), as described [100], plates were centrifuged at 500g for 5 
minutes and incubated for 1 or 2 hours, after which cells were washed gently 3x in warm 
PBS and gently removed from the plate using a cell scraper. Cells were washed 2x with 
ice-cold PBS and supernatant discarded following centrifugation. Washed cells were then 
resuspended in flow buffer and analyzed by flow cytometry using a BD LSRII flow 
cytometer. As a negative control, untreated cells and cells incubated with unlabeled B.  
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Confocal microscopy 
 Peritoneal macrophages were harvested as described above and allowed to adhere 
to the surface of etched microscope cover slides for 4 hours. Cells were incubated with 
GFP-B. burgdorferi for 1 hour at a 100:1 MOI as described above, followed by 4x 
washes with warm PBS, fixed in 4 percent paraformaldehyde, and incubated with 
antibody blocking solution (3 percent BSA 0.05 percent milk 0.2 percent Tween20 in 
PBS) for 1 hour at RT. Cells were then stained with PE-conjugated LAMP-1, APC-
conjugated F4/80, and DAPI for 1 hour in antibody solution (1 percent BSA 0.02 percent 
Tween20 in PBS), washed and mounted onto a glass slide using fluorescent mounting 
reagent (Calbiochem EMD Millipore). Confocal imaging was performed on a FV1000 
inverted confocal microscope (Olympus) using FV10-ASW software (Olympus). Images 
were taken using a 60x oil lens with a 1024x1024 2x zoom, and captured at a plane 
dissecting the middle of cell nuclei. All imaging was performed at the University of Utah  
Cell Imaging Core Facility, with the assistance of Dr. Christopher Rodesh. 
 
 
Data and statistical analysis 
 Microarray data statistical analysis was performed using the Agilent Feature 
Extraction Software (v.10.5) and Geospiza GeneSifter Analysis Edition (Perkin Elmer), 
as described. Raw and adjusted p values were derived by Welch’s t test with Benjamini 
and Hochberg correction, using a raw p value cutoff of p < 0.05 signifying statistical 
significance. All other graphical data represent the mean ± SEM. Statistical analysis was 
performed using Prism 5.0c software. Multiple-sample data sets were analyzed by one-
way ANOVA with Dunnet’s or Tukey’s post hoc test for pair-wise comparisons, as 
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appropriate and indicated in figure legends. Two-sample data sets were analyzed by 
Student t test. Categorical data for histopathology were assessed by Mann-Whitney U  
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Figure 3.1. PCR validation of miRNA microarray results. qRT-PCR analysis of miR-
146a, miR-21, and miR-155 expression normalized to 5S rRNA from B. burgdorferi-
infected joints of B6, C3H, and IL-10-/- mice at 1, 2, or 4 weeks postinfection (n=3-4). 
Shown is fold change in expression compared to uninfected controls ± SEM. * indicates 
statistically significant increase in expression vs. uninfected controls by ANOVA 
followed by Dunnett’s post-hoc test, α=0.05. 
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Figure 3.2. B6 miR-146a-/- mice develop more severe arthritis at 4 weeks 
postinfection independent of bacterial burden. Arthritis severity was determined for B. 
burgdorferi-infected B6 or B6 miR-146a-/- mice at 4 weeks postinfection. (A) Blinded 
measurements of rear ankles of mice were taken before infection and at 4 weeks 
postinfection, and change in ankle measurement is shown. (B) Representative images of 
H&E-stained tibiotarsal joints from BSK-injected (control) and 4 week-infected B6 and 
B6 miR-146a-/- mice used for histopathology scoring (see Table 3.2). Cranial tibial 
tendons of infected joints are enlarged to show detail of tendon sheath thickening and 
PMN infiltrate. (C) Bacterial burden was determined by quantifying B. burgdorferi-
specific 16S rRNA normalized to 1000 β-actin for joint and heart tissue, and recA, 
normalized to 1000 nidogen for ear tissue. Pooled from two independent infection 
experiments (n≥9 mice per experiment) for joints, and from one experiment for heart and 
ear tissue (n=5 mice). Statistical significance was determined by Student t test (*p<0.01). 
(D) Antibody concentrations were estimated in serum collected from B. burgdorferi-
infected B6 and B6 miR-146a-/- mice as described in materials and methods. IgM was 
measured at 2 weeks postinfection (n=4) and IgG was measured at 4 weeks postinfection 
(n=9-10). Data are representative of 2 independent experiments (n.s.: no significant 
difference between strains). 
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Figure 3.3. B6 and B6 miR-146a-/- mice have similar B. burgdorferi burden and 
similar levels of inflammation in heart tissue, distinct from C3H mice. Mice were 
infected with B. burgdorferi for 3 weeks, after which hearts were collected for analysis of 
bacterial burden and inflammation. (A) Bacterial presence was quantified with B. 
burgdorferi-specific 16S rRNA, normalized to 1000 β-actin by qRT-PCR. (B) Carditis 
was blindly assessed using histopathologic evaluation to score lesion severity in heart 
tissue from B6, B6 miR-146a-/-, and C3H mice infected with B. burgdorferi for 3 weeks. 
(C) H&E-stained sections of infected B6, B6 miR-146a-/-, and C3H hearts (10x 
magnification top row, 40x magnification bottom row), with the intraventricular septum 
(ivs), coronary artery (ca), pulmonary artery (pa), and aorta (a) labeled as indicated. The 
inflammatory response in these lesions was a mixture of neutrophils and mononuclear 
inflammatory cells such as lymphocytes and macrophages. (D) Transcripts for CD11b, 
F4/80, CD4 and Vα14, IFNγ and IL6 were measured by qRT-PCR, normalized to β-actin. 
4 mice were used for each strain, and statistically significant difference between groups 
by ANOVA followed by Tukey’s post-hoc test are indicated (*p<0.05). For lesion 
scoring, Mann-Whitney U test was used to determine whether there were statistical 
significant differences between groups, with p value indicated (n=4 mice per strain). 
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Figure 3.4. B6 miR-146a-/- mice exhibit hyperactive expression of a subset of NF-κB 
target cytokines and chemokines at 4 weeks postinfection. (A) RNA was isolated from 
B. burgdorferi-infected rear ankle joints at 2 and 4 weeks postinfection and transcript 
levels of IL6, IL1β, Cxcl1, Cxcl2, IFNγ, Cxcl10, and TNFα were measured by qRT-PCR, 
normalized to β-actin. (B) Serum from B. burgdorferi-infected mice was collected by 
cheek bleed at 4 weeks postinfection, and IL-6, TNFα, IL-12, and IFN-γ protein 
concentration was measured by ELISA. Statistically significant differences between 
groups by ANOVA followed by Tukey’s post-hoc test are indicated (*p<0.05, n≥9 mice 
per group). 
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Figure 3.5. Effect of miR-146a in isolated joint cell populations early in infection. 
(A) FACS analysis of cells released from joint tissue of B6 mice uninfected or infected 
with B. burgdorferi for 7 or 14 days. Single-cell suspensions of tissue were prepared as 
described in materials and methods, and cells were stained according to myeloid (CD45+ 
CD11b+), lymphoid (CD45+ CD11b-), endothelial (CD45- CD31+), or fibroblast-
enriched (CD45- CD31- CD29+) lineages, following gating to exclude debris, dead cells, 
and cell doublets. (B) Cells sorted into various lineages depicted in (A) were analyzed for 
transcript levels of Cxcl2, IL1β, and Oasl2 in myeloid cells, Cxcl1 in fibroblast-enriched 
cells, and IFNγ in lymphoid cells, normalized to β-actin. Data are representative of two 
independent experiments (n=4 mice for each group). 
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Figure 3.6. Myeloid cell recruitment is increased in infected joints of B6 miR-146a-/- 
mice. (A) Representative flow cytometry analysis of CD11b+ cells released from joint 
tissue of B6 or B6 miR-146a-/- mice infected with B. burgdorferi for 2 or 4 weeks, 
following gating to exclude debris, dead cells, and cell doublets. Numbers indicate gate 
percentages. (B) Representative histogram showing MRC1 (Mannose Receptor, C type 1, 
CD206) and Gr1 fluorescent intensity in macrophages (Mϕ), polymorphonuclear cells 
(PMNs), and monocyte gates, as shown in (A). Gray shaded area indicates B6 mice and 
the black line indicates B6 miR-146a-/- mice. Bar graph on right shows average mean 
fluorescence intensity of macrophages, PMNs, and monocytes isolated from 14 day-
infected B6 or miR-146a-/- mouse joints (n=4). (C) Total numbers of myeloid cell 
populations in joints of uninfected or B. burgdorferi-infected mice at 2 and 4 weeks 
postinfection from B6 or B6 miR-146a-/- mice. Cell populations were identified by flow 
cytometric analysis with macrophages defined as CD11b+ F4/80+ Ly6Clo, 
polymorphonuclear cells (PMNs) as CD11b+ Gr1hi Ly6Cint, and monocytes as CD11b+ 
Gr1int Ly6Chi. Statistically significant differences between groups by ANOVA followed 
by Tukey’s post-hoc test are indicated (*p<0.05). For selected values not reaching 
statistical significance cutoff, p values are listed. Representative of 2 independent 
experiments (n=4 for each group). 
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Figure 3.7. Bone marrow-derived Macrophages from B6 miR-146a-/- mice are 
hyper-responsive to B. burgdorferi and have elevated levels of TRAF6. (A) Analysis 
of cytokine secretion of B. burgdorferi-treated BMDMs. Bone marrow-derived 
macrophages (BMDMs) from B6 (black) or B6 miR-146a-/- (white) mice were pretreated 
for 4 hours in the presence or absence of recombinant mouse IL-10. Following 
pretreatment, cells were stimulated with B. burgdorferi for 24 hours. Cell supernatant 
was collected and secretion of IL-6, IL-1β, CXCL1, IL-12, TNFα, and IL-10 was 
measured by ELISA. (B) Immunoblot analysis of TRAF6, IRAK1, and STAT1 in B. 
burgdorferi-treated BMDMs from B6 (WT) or B6 miR-146a-/- (KO) mice. BMDMs were 
stimulated with media alone or B. burgdorferi for 24 hours and cells were lysed using 
NP-40. Quantification was determined based on band intensity, normalized to β-actin, 
with B6 (WT) value set to 1. (C) Traf6, Irak1, and Stat1 mRNA levels were quantified 
using qRT-PCR, normalized to β-actin. Significant differences between groups by 
ANOVA followed by Tukey’s post-hoc test are indicated (*p<0.05). Representative of at 
least 2 independent experiments (n=3-4 for each group). 
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Figure 3.8. B6 miR-146a-/- peritoneal macrophages exhibit increased phagocytic 
activity. (A) Representative plots of peritoneal macrophages isolated from B6 or B6 
miR-146a-/- mice and incubated with GFP-B. burgdorferi for 1 or 2 hours at 10:1 MOI. 
Box indicates GFP+ fraction, and number in top-right corner is percent GFP+. Control is 
using cells only. (B) Mean percent GFP+ and GFP mean fluorescence intensity for flow 
analysis shown in (A). Representative of two independent experiments (n=3 for each 
experiment). Significant differences between groups by ANOVA followed by Tukey’s 
post-hoc test are indicated (*p<0.05). (C) Confocal images of B6 peritoneal macrophages 
incubated with GFP-B. burgdorferi for 1 hour at 100:1 MOI. Panels are (from top-left) 
cell nuclei (gray, DAPI), GFP-B. burgdorferi (green), lysosomes (red, LAMP-1), cell 
membrane (blue, F4/80), bright-field, and overlaid images. White bar indicates scale. 
White arrow shows a bacterium associated with a macrophage pseudopod, chevron 
indicates bright GFP puncta associated with intracellular lysosomes, and triangle 
indicates a cell surface-associated bacterium. Representative of two biological replicates. 
Similar images of B6 miR-146a-/- macrophages can be found in supplemental data. 
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Figure 3.9. Model of miR-146a function as a suppressor of arthritis during 
persistent B. burgdorferi infection.  Regulatory role of miR-146a in myeloid cells 
present in joint tissue as a negative regulator of Toll-like receptor (TLR) signaling 
through suppression of adaptor proteins, particularly TRAF6. 
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Figure 3.S1. Lymphocyte infiltration into joints of B. burgdorferi-infected mice is 
similar between WT and miR-146a-/- mice. Flow cytometry analysis of lymphoid cells 
released from joint tissue of B6 or B6 miR-146a-/- mice infected with B. burgdorferi for 2 
or 4 weeks, following gating to exclude debris, dead cells, and cell doublets. Cell lineages 
defined as follows: T cells (CD45+ TCRβ+), B cells (CD45+ B220+), and NK cells 
(CD45+ NK1.1+). No significance was observed between any groups by ANOVA 
followed by Tukey’s post-hoc test (*p<0.05). 
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Figure 3.S2. Confocal images of B6 miR-146a-/- peritoneal macrophages incubated 
with GFP-B. burgdorferi. Panels are (from top-left) cell nuclei (gray, DAPI), GFP-B. 
burgdorferi (green), lysosomes (red, LAMP-1), cell membrane (blue, F4/80), bright-field, 
and overlay fields. White bar indicates scale. 
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Table 3.1. MicroRNAs most highly changed in expression, based on microarray, in 
joints of different mouse strains.   
 
B6 C3H IL-10-/- 
miRNA Fold Δ miRNA Fold Δ miRNA Fold Δ 
miR-146a 5.67 miR-146a 10.8 miR-21 6.08 
miR-21 3.92 miR-21 8.12 miR-146a 5.34 
miR-706 3.47 miR-142-3p 6.54 miR-155 5.12 
miR-29b 2.31 miR-142-5p 4.99 miR-193b -3.04 
miR-715 2.24 miR-34a 4.4 miR-150 -2.56 
miR-340-5p 2.21 miR-18a 3.35 miR-145 -2.43 
miR-34a 2.16 miR-19b 3.08 miR-181a -2.37 
miR-689 2.12 miR-145 -3.07 miR-181b -2.29 
 
List of 8 most highly differentially expressed miRNAs in B. burgdorferi-infected joints 
of B6, C3H, and B6 IL-10-/- mice at 2 weeks postinfection, based on Agilent mouse 
miRNA microarray. Shown is fold-change in expression compared to uninfected controls. 
Significance was determined using Welch's t-test with Benjamini and Hochberg 
correction (p<0.05, n=3-4 mice per group). 
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Table 3.2. Histopathology scores of arthritis severity for B6 and B6 miR-146a-/- 
mice. 
 












B6 1.53 (.21) 1.05 (.25) 0.58 (.14) 1.42 (.22) 0.26 (.15) 4.84 (.79) 
miR-146a-/- 2.84 (.26) 2.21 (.26) 0.37 (.11) 2.74 (.26) 1.58 (.25) 9.74 (.97) 
 
Histopathology scores of rear ankle joints of B6 and B6 miR-146a-/- mice infected with 
B. burgdorferi for 4 weeks. Scores of 0-5, with 5 being most severe, were assigned to 
each sample. Total score is the sum of scores from each category. Values shown are the 
mean (±SE), and bold numbers indicate statistically significant difference between strains 
using Mann-Whitney U test (p<0.01), pooled from two independent infection 
experiments (n=9-10 each). 
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Table 3.3. mRNA expression of induced cytokines in BMDMs from B6 and B6 miR-
146a-/- mice after 6 and 24 hours stimulation with B. burgdorferi. 
 
Strain 6 hours 24 hours 
 IL1β IL6 TNFα IL1β IL6 TNFα 
B6 56.2±2.5 0.008±0.002 127.3±6.6 109.7±12.7 1.07±0.46 6.42±0.58 
miR-146a-/- 236±8.7 0.06±0.007 168.2±14.7 446.8±14.0 2.67±0.35 7.91±0.37 
Fold Δ 4.2 7.5 1.3 4.1 2.5 1.2 
 
Induced transcript levels of IL1β, IL6, and TNFα (normalized to 1000 β-actin) in B6 and 
B6 miR-146a-/- BMDMs stimulated with B. burgdorferi for 6 or 24 hours. Data shown 
are mean±SE, as well as fold-difference (Fold Δ) of expression in miR-146a-/- vs. B6. 
Transcript levels of uninfected cells were very low and similar between strains (not 
shown). Representative of 3 independent experiments (n≥3 for each experiment). 
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Table 3.S1. MicroRNAs with greater than 2-fold change in expression in joints of 
mouse strains, based on Agilent miRNA microarray analysis. 
 
Group 1: B6 control    
Group 2: B6 week 1    
Statistics: Welchs t-test   
Correction: Benjamini and Hochberg  
Gene Identifier Ratio Direction p-value adj. p-value 
mmu-miR-139-3p 2.74 Down 0.0136889 0.0211556 
mmu-miR-466g 2.58 Down 0.0036082 0.0068155 
mmu-miR-466f-3p 2.49 Down 0.0011125 0.0063042 
mmu-miR-202-3p 2.29 Down 0.0031243 0.0066392 
mmu-miR-466i 2.28 Down 0.0018722 0.0064726 
mmu-miR-689 2.27 Up 5.069E-04 0.0043087 
mmu-miR-21 2.14 Up 6.63E-05 0.0011274 
mmu-miR-18a 2.04 Up 0.0026652 0.0064726 
mmu-miR-467f 2.04 Down 0.0020589 0.0064726 
mmu-miR-494 2.03 Up 0.0026516 0.0064726 
mmu-miR-29b 2.01 Up 0.0075675 0.0128647 
     
Group 1: B6 control   
Group 2: B6 week 2   
Statistics: Welchs t-test   
Correction: Benjamini and Hochberg  
Gene Identifier Ratio Direction p-value adj. p-value	  
mmu-miR-146a 5.67 Up 1.765E-04 0.0065313 
mmu-miR-21 3.92 Up 0.0054998 0.0422948 
mmu-miR-706 3.47 Up 0.0068586 0.0422948 
mmu-miR-29b 2.31 Up 0.0314381 0.1292457 
mmu-miR-715 2.24 Up 0.0027000 0.0369090 
mmu-miR-340-5p 2.21 Up 0.0247291 0.1143724 
mmu-miR-34a 2.16 Up 0.0065130 0.0422948 
mmu-miR-689 2.12 Up 0.0239135 0.1143724 
mghv-miR-M1-2 2.01 Up 0.0029926 0.0369090 
     
Group 1: C3H control    
Group 2: C3H week 1   
Statistics: Welchs t-test   
Correction: Benjamini and Hochberg   
Gene Identifier Ratio Direction p-value adj. p-value	  
mmu-miR-144 10.72 Up 0.0059985 0.0118504 
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Table 3.S1. Continued    
mmu-miR-466f-3p 7.74 Down 0.0208671 0.0225365 
mmu-miR-136 6.63 Up 0.0015580 0.0071312 
mmu-miR-720 6.13 Up 0.0036499 0.0109498 
mmu-miR-466i 6.1 Down 0.0074614 0.0118504 
mmu-miR-142-3p 5.92 Up 0.0072559 0.0118504 
mmu-miR-142-5p 5.01 Up 0.0030635 0.0103393 
mmu-miR-301a 4.96 Up 0.0116770 0.0153280 
mmu-miR-467f 4.71 Down 0.0090167 0.0135251 
mmu-miR-1187 3.57 Down 0.0013349 0.0071312 
mmu-miR-574-5p 3.31 Down 0.0015847 0.0071312 
mmu-miR-669n 3.28 Down 3.785E-04 0.0051109 
mmu-miR-19b 2.96 Up 0.0129689 0.0153280 
mmu-miR-376a 2.88 Up 2.651E-04 0.0051109 
mmu-miR-101a 2.88 Up 0.0121775 0.0153280 
mmu-miR-574-3p 2.61 Down 0.0388088 0.0388083 
mmu-miR-29a* 2.6 Up 0.0068457 0.0118504 
mmu-miR-18a 2.55 Up 0.0050183 0.0112913 
mmu-miR-338-3p 2.43 Up 6.400E-04 0.0057607 
mmu-miR-21 2.33 Up 0.0040851 0.0110298 
mmu-miR-145 2.26 Down 0.0074154 0.0118504 
mmu-miR-669f 2.21 Down 0.0044967 0.0110375 
mmu-miR-340-5p 2.21 Up 0.0095250 0.0135355 
mmu-miR-434-5p 2.19 Up 0.0361220 0.0375114 
mmu-miR-101b 2.09 Up 0.0130571 0.0153280 
mmu-miR-30e 2.06 Up 0.0188380 0.0211928 
mmu-miR-7a 2.04 Up 0.0028723 0.0103393 
     
Group 1: C3H control    
Group 2: C3H week 2    
Statistics: Welchs t-test    
Correction: Benjamini and Hochberg  
Gene Identifier Ratio Direction p-value adj. p-value 
mmu-miR-146a 10.8 Up 8.35443E-04 5.64E-03 
mmu-miR-21 8.12 Up 5.09E-07 1.37E-05 
mmu-miR-142-3p 6.54 Up 0.004686706 1.27E-02 
mmu-miR-142-5p 4.99 Up 0.011309152 1.70E-02 
mmu-miR-34a 4.4 Up 2.43294E-04 3.28E-03 
mmu-miR-18a 3.35 Up 0.001501822 6.76E-03 
mmu-miR-19b 3.08 Up 0.00711288 1.36E-02 
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Table 3.S1. Continued    
mmu-miR-145 3.07 Down 0.006830074 1.36E-02 
mmu-miR-342-3p 3.01 Up 0.018902847 2.55E-02 
mmu-miR-7a 2.92 Up 0.004152087 1.25E-02 
mmu-miR-466g 2.84 Down 0.013821859 1.96E-02 
mmu-miR-466f-3p 2.78 Down 0.003301523 1.11E-02 
mmu-miR-340-5p 2.73 Up 0.010107969 1.61E-02 
mmu-miR-130b 2.65 Up 0.001815616 7.00E-03 
mmu-miR-362-5p 2.51 Up 6.84423E-04 5.64E-03 
mmu-miR-466i 2.36 Down 0.007286134 1.36E-02 
mmu-miR-17* 2.28 Up 0.00761823 1.36E-02 
mmu-miR-29b 2.27 Up 0.027154031 3.49E-02 
mmu-miR-146b 2.18 Up 0.001483454 6.76E-03 
mmu-miR-574-3p 2.11 Down 0.008046157 1.36E-02 
mmu-miR-467f 2.07 Down 0.007130363 1.36E-02 
     
Group 1: IL10 ko control   
Group 2: IL10 ko week 1   
Statistics: Welchs t-test   
Correction: Benjamini and Hochberg  
Gene Identifier Ratio Direction p-value adj. p-value 
mmu-miR-133a 2.19 Up 0.011191776 0.01939199 
mmu-miR-133b 2.14 Up 0.012927996 0.01939199 
mmu-miR-146a 2.05 Up 0.041399321 0.04139932 
     
Group 1: IL10 ko control   
Group 2: IL10 ko week 2   
Statistics: Welchs t-test   
Correction: Benjamini and Hochberg  
Gene Identifier Ratio Direction p-value adj. p-value	  
mmu-miR-21 6.08 Up 5.98E-06 1.19505E-04 
mmu-miR-146a 5.34 Up 3.85517E-04 0.003344354 
mmu-miR-155 5.12 Up 5.01653E-04 0.003344354 
mmu-miR-193b 3.04 Down 0.006862146 0.015113973 
mmu-miR-150 2.56 Down 0.001735425 0.008677123 
mmu-miR-145 2.43 Down 0.007556986 0.015113973 
mmu-miR-181a 2.37 Down 0.005549417 0.015113973 
mmu-miR-181b 2.29 Down 0.011713074 0.018020113 
mmu-let-7b 2.17 Down 0.016701305 0.020876632 
mmu-miR-151-5p 2.16 Down 0.011158357 0.018020113 
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Table 3.S1. Continued    
mmu-let-7c 2.15 Down 0.018191511 0.021401778 
mmu-miR-195 2.14 Down 0.015536991 0.020876632 
mmu-miR-196b 2.14 Down 0.01946987 0.021633189 
mmu-miR-199b* 2.09 Down 0.026609241 0.026609241 
mmu-miR-497 2.08 Down 0.016139593 0.020876632 
mmu-miR-365 2.07 Down 0.022465838 0.023648251 
mmu-miR-23b 2.07 Down 0.006067439 0.015113973 
mmu-miR-142-3p 2.07 Up 0.008642346 0.015713356 
mmu-miR-7a 2.07 Up 0.006185229 0.015113973 
mmu-miR-342-3p 2.01 Up 0.002969385 0.011877542 	  
All microRNAs with greater than 2-fold change in expression in B. burgdorferi-infected 
joints of B6, C3H, and B6 IL-10-/- mice at 1 and 2 weeks postinfection, compared to 
uninfected controls, based on Agilent mouse miRNA microarray. Shown is gene name, 
fold-change, direction of fold-change, p-value and adjusted p-value. Significance was 
determined using Welch's t-test with Benjamini and Hochberg correction (p<0.05, n=3-4 
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Overview 
 The immune system is a network of various cell types, tissues, and organs, working 
in concert to detect and eliminate pathogens. Upon infection, rapid and robust innate 
immune activation is required to limit pathogen spread. While this is important in host 
defense, pathogen-mediated inflammation also leads to tissue damage. It is therefore also 
essential for the immune response to be tightly regulated in terms of both amplitude and 
duration, and to fully resolve following pathogen clearance. Failure to properly regulate 
an immune response to infection can lead to inflammatory disease and autoimmunity. 
Lyme arthritis is an excellent example of an inflammatory disease caused by infection of 
an arthritogenic pathogen, Borrelia burgdorferi [1]. Infection can trigger a wide range of 
disease severity, from mild joint pain and acute arthritis, to severe prolonged treatment-
refractory arthritis [2]. This chronic inflammation in some cases primes the immune 
system to develop autoimmune arthritis [3,4]. Thus, this disease can be used as a model 
for elucidating the link between pathogen-induced inflammation and development of 
autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, 
multiple sclerosis, and type 1 diabetes [5-8]. 
 The mouse model of Lyme arthritis is a powerful tool in elucidating the molecular 
and genetic mechanisms of pathological inflammation. Mice are natural hosts for the 
pathogen [9], disease pathology in mice is similar in many ways to human disease [10], 
and many immunological tools are available in the mouse model system, allowing for 
very sophisticated study of this disease [11]. Lyme disease research has yielded many 
important discoveries about inflammation, immune function, and host-pathogen 
interactions [12]. Building upon these previous discoveries, this thesis identifies novel 
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Cellular Sources of Type I Interferon in Lyme Arthritis 
 A robust type I IFN response early in infection with B. burgdorferi was initially 
identified in joints of arthritis-susceptible C3H mice by microarray analysis [13]. This led 
to the hypothesis that dysregulation of type I IFN early in infection contributes to 
increased Lyme arthritis later in infection. This hypothesis was tested by Miller et al. [14] 
using a neutralizing antibody targeting the type I interferon receptor (IFNAR), and 
confirmed using a knockout C3H IFNAR-/- mouse, shown in Chapter 2. These two 
experiments supported this hypothesis, directly linking preclinical dysregulation of type I 
interferon to severe arthritis later in infection.  
 Arthritic joint tissue is a complex array of many cell types, including immune cells 
such as macrophages, neutrophils, B cells, and T cells; as well as resident cells, including 
endothelial cells, fibroblasts, and chondrocytes. Many cell types are capable of producing 
and responding to type I IFN [15]. It was therefore important to identify the relevant cell 
types contributing to the pathological upregulation of the interferon expression profile. 
Because of the complex nature of joint tissue, identifying the relevant cell types ex vivo 
required development of novel methods of analysis. A system of isolating joint cells 
followed by cell sorting allowed for ex vivo analysis of various cell lineages. This method 
was utilized to show that (1) while both resident and hematopoietic cells from naïve 
mouse joints were capable of responding to B. burgdorferi stimulation, only 
hematopoietic cells were able to initiate a type I IFN response; and (2) endothelial cells 
and fibroblasts were primary contributors of the type I IFN response in infected mouse 
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joints. This highlights the importance of studying complex biological systems within the 
context of their cellular environment, and emphasizes the critical role of resident cells in 
immune function and disease pathogenesis. The clinical relevance of this finding is 
supported by a recent patient study suggesting that excessive endothelial cell activation 
and proliferation through production of ECGF can contribute to autoimmunity in many 
Lyme arthritis patients [4]. 
 It has been known for over 35 years that lupus patients produce very high levels of 
type I IFN [16], which is produced by plasmacytoid dendritic cells responding to self 
nucleic acids through TLRs and other pathogen recognition receptors [17]. Furthermore, 
there are cases where individuals undergoing interferon treatment for hepatitis C have 
developed clinical systemic lupus erythematosus [18,19]. The strong connection between 
lupus and type I IFN has resulted in testing of potential anti-interferon pharmaceuticals as 
a therapeutic [20].  
 It has also recently been reported that children predisposed to type 1 diabetes 
exhibit a preclinical type I IFN signature prior to disease onset, but this signature is 
absent in patients with active disease [21]. Furthermore, this signature is likely the result 
of a heritable hyperactive type I IFN response to viral infection [22,23]. This is strikingly 
similar to our observations in C3H mice, which have a robust and transient preclinical 
type I IFN signature early in infection with B. burgdorferi [13], and contributes to disease 
severity, as shown in Chapter 2 and by Miller et al. [14]. Thus, elucidating the molecular 
mechanisms of the arthritogenic type I IFN response in the C3H mouse model of Lyme 
arthritis may provide critical insight into not only Lyme arthritis development, but lupus 
and type 1 diabetes as well. 
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MicroRNA-146a Is an Immune Modulator in Lyme Arthritis 
 Since their discovery, microRNAs have been shown to be important regulators of 
many cellular processes, including immune response to infection, inflammation, and 
autoimmunity [24]. Several microRNAs, including miR-146a and miR-155, have been 
shown to be upregulated through TLR-mediated NF-κB activation, and act as negative 
and positive regulators of inflammation, respectively [25,26]. These and other 
microRNAs are also associated with inflammatory and autoimmune diseases [27], 
suggesting that microRNAs play a role in disease pathogenesis. Because of this, it was 
reasonable to predict that microRNAs also played a role in regulating the immune 
response to B. burgdorferi. 
 As discussed in Chapter 3, expression analysis of microRNAs differentially 
expressed in joints of infected C3H, B6, and B6 IL10-/- mice revealed that a number of 
microRNAs were upregulated and downregulated in joints at 1 and 2 weeks 
postinfection. Of the over 600 microRNAs examined, only several dozen showed 
significant changes in expression during infection. Each mouse strain contained a unique 
set of microRNAs differentially expressed, as well as a small number of microRNAs 
whose expression profile was similar between two or more strains. Among those shared 
by all three strains was miR-146a, previously identified as an important negative 
regulator of NF-κB activation [28]. This microRNA was highly upregulated in all three 
strains, suggesting that it plays an important immune-modulatory role in response to B. 
burgdorferi infection.  
 MicroRNA-146a functions as an negative feedback regulator of NF-κB activation 
by suppressing translation of IRAK1 and TRAF6, proteins involved in TLR signaling 
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[25]. TLR-mediated activation of the innate immune response is critical in controlling B. 
burgdorferi infection [29], so it was not surprising to find that this important regulator 
was upregulated. It was unknown, however, whether this observation had functional 
relevance in the context of Lyme arthritis. Fortunately, a B6 miR-146a-/- mouse was 
available [30], so it was possible to ask whether arthritis-resistant mice lacking this 
negative NF-κB regulator would develop more severe arthritis, and if there would be an 
effect on host defense. 
 Upon infection, B6 mice lacking miR-146a develop more severe arthritis than wild-
type B6 mice, and exhibit a hyperactive NF-κB response. Furthermore, these mice had 
modestly fewer numbers of bacteria in their joints, had similar B. burgdorferi numbers in 
heart and skin tissue, and had similar carditis compared to wild-type mice. This finding 
was significant for two reasons: first, it demonstrated that microRNA-mediated 
regulation was required for suppression of joint inflammation; second, this finding 
showed for the first time that hyperactive TLR/NF-κB activation led to increased arthritis 
severity. While this had long been suspected, it was difficult to show definitively, since 
mice lacking TLR2 or the adapter protein MyD88 have a severe host defense defect, 
contain extremely high numbers of bacteria in joints and other tissue, and still develop 
severe arthritis, despite having a defective pro-inflammatory TLR/MyD88/NF-κB 
signaling pathway [29,31]. In contrast, the B6 miR-146a-/- mouse had only a modest 
effect on host defense and increased the amplitude of this signaling pathway, thereby 
acting as a “fine tuner” of NF-κB activation [32]. The observation that these mice still 
develop severe arthritis shows that the amplitude of this signaling pathway is directly 
linked to pathological inflammation. 
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 Another important finding in these studies was that B6 miR-146a-/- macrophages 
responded to B. burgdorferi stimulation in distinct ways. For example, peritoneal 
macrophages from B6 miR-146a-/- mice were more highly phagocytic than wild-type B6 
peritoneal macrophages. This finding shows that miR-146a is involved in regulation of 
phagocytic activity, although the precise molecular mechanism remains unknown. 
Additionally, bone marrow-derived macrophages were refractory to treatment with the 
anti-inflammatory cytokine IL-10, and still produced high levels, compared to wild-type 
macrophages, of pro-inflammatory cytokines and chemokines after B. burgdorferi 
stimulation. This was likely due to significantly elevated protein levels of TRAF6, a  
protein important in TLR/NF-κB activation. 
 
 
Roles of miR-155 and IL-10 in Host Response to B. burgdorferi 
 In addition to miR-146a, miR-155 was also identified in the microRNA microarray. 
Unlike miR-146a, however, this pro-inflammatory microRNA was exclusively 
upregulated in arthritic B6 IL10-/- mouse joints (Chapter 3). This finding suggests that IL-
10 suppresses miR-155 expression in mouse joints, which was shown to occur in 
macrophages by McCoy et al. [33]. IL-10 is a key anti-inflammatory cytokine and is 
critical in limiting a wide range of inflammatory responses through downregulation of 
Th1 cytokines, inhibition of NF-κB activity, and suppression of M1 macrophage activity 
[34]. IL-10 is also an important regulator of Lyme arthritis severity in mice and humans 
[35,36]. In contrast to IL-10, miR-155 is a pro-inflammatory microRNA that targets 
several immune genes, including the transcription factor PU.1 and two negative 
regulators, SHIP1 and SOCS1, suppressors of AKT and IFN signaling, respectively [37]. 
Furthermore, miR-155 regulates myeloid cell, T-cell, and B-cell function [26,38-40], and 
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is critical in regulating hematopoiesis and autoimmunity [41,42]. Importantly, elevated 
miR-155 expression is associated with inflammatory diseases such as lupus [43] and 
rheumatoid arthritis [44]. 
 There was reason to think that IL-10-mediated regulation of miR-155 was 
functionally relevant, since others have shown several opposing immune phenotypes in 
mice lacking either IL-10 or miR-155. For example, compared to wild-type B6 mice, B6 
IL10-/- mice exhibit increased Lyme arthritis [45], have an arthritogenic IFNγ signature 
[35], develop severe lymphadenopathy and produce high levels of B. burgdorferi-specific 
antibodies [46], and have a dysregulated innate immune response, which contributes to 
increased arthritis severity and elevated bacterial clearance [46,47]. Also, administration 
of exogenous IL-10 limited collagen-induced arthritis progression in mice [48] (but not 
Lyme arthritis [49]). Conversely, B6 miR-155-/- mice have impaired B cell response and 
IgG class switching [39,40,50], reduced IFNγ production by T cells [42], and are 
protected from autoimmune arthritis [51]. However, no studies had been done to 
determine to what degree the immunosuppressive activity of IL-10 was due to its 
downregulation of the proinflammatory microRNA miR-155.  
 To test whether this IL-10-mediated miR-155 suppression affects host response to 
B. burgdorferi and Lyme arthritis development, a B6 IL10-/- miR-155-/- double knockout 
(DKO) mouse was generated (Appendix A). Using this mouse in the context of Lyme 
borreliosis, it was found that many, but not all, immune modulatory effects of IL-10 are 
dependent upon IL-10-mediated suppression of miR-155.  
 Upon infection, B6 IL10-/- miR-155-/- DKO mice had lower levels of B. 
burgdorferi-specific IgG than either B6 IL10-/- or wild-type B6 mice, and nearly 
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undetectable levels of the IgG1 isotype, consistent with previous observations in the B6 
miR-155-/- mouse [39], suggesting that miR-155 is absolutely required for IgG1 
production. Interestingly, while IL-10 deficiency resulted in elevated IgG2C isotype 
levels over wild-type, lack of miR-155 resulted in levels of IgG2C similar to wild-type, 
and DKO mice had IgG2C levels similar to both B6 and B6 miR-155-/- mice. These data 
show that miR-155 is not required for IgG2C class switching (in contrast to IgG1), and 
that IL-10-mediated regulation of miR-155 regulates IgG2C production.  
 This difference in IgG production and class switching, however, had no influence 
on arthritis severity or host defense. This is consistent with previous data showing IgG1 
isotype production does not influence Lyme arthritis [52]. Whereas B6 and B6 miR-155-/- 
mice developed mild Lyme arthritis and had moderate numbers of spirochetes in joint 
tissue, B6 IL-10-/- and DKO mice developed severe arthritis while harboring very low 
numbers of bacteria. These data show that immune suppressor functions of IL-10 
independent of miR-155 regulation were overwhelmingly responsible for increased 
arthritis severity and enhanced host defense. This was also seen for serum levels of IL-12, 
a cytokine involved in macrophage activation of T cells, which was significantly elevated 
in both strains lacking IL-10, but was not elevated in the two IL-10-sufficient strains. 
Similarly, the IFNγ profile was upregulated in both B6 IL10-/- and DKO mouse joint 
tissue, but not in B6 or B6 miR-155-/- mice. This was due in part to the complex cellular 
environment of the joint, since the IFN profile of macrophages stimulated with B. 
burgdorferi was largely dependent upon the presence of miR-155, and the enhanced 
upregulation of interferon-inducible genes such as Cxcl9 and Cxcl10 seen in IL10-/- 
macrophages returned to near wild-type levels in DKO macrophages. Also consistent 
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with a cell environment-dependent miR-155 effect on IFNγ, serum levels of IFNγ were 
somewhat reduced in the DKO mouse, compared to the B6 IL10-/- mouse, suggesting a 
role of miR-155 in systemic, but not localized IFN production. This also points to joint-
localized IFNγ production, rather than systemic IFN levels, as being the arthritogenic IFN 
source. Overall, these data show that there are distinct and opposing roles of miR-155 and 




MicroRNAs in the Clinical Setting 
 These and other studies have clearly shown that microRNAs play a critical role in 
modulating numerous signaling pathways, and that defects in microRNA function often 
leads to disease [37]. Naturally, one may speculate that microRNA-based therapeutics 
may be an attractive new class of drugs. While there is some promise for use of miRNA-
targeted therapy for HCV patients [53], large barriers exist for miRNA-based treatment, 
particularly in regards to microRNA delivery. Some progress has been made in the use of 
exosomes and macromolecules for cell- and tissue-specific microRNA delivery, and 
efforts are underway to develop novel methods of using both miRNA antagonists and 
miRNA mimics in a clinical setting [54-60].  
 Of more immediate clinical interest is the potential of microRNAs as a diagnostic 
tool [61]. Many microRNAs are secreted into the bloodstream, allowing for microRNA 
screening to be performed during routine blood testing, and abnormally high or low 
levels of certain microRNAs may be a molecular biomarker of dysregulated pathways 
[61]. In the case of Lyme arthritis, the microarray screen discussed in Chapter 3 showed 
that arthritis-susceptible C3H and B6 IL10-/- mice have very distinct microRNA 
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expression profiles, likely reflecting the different mechanisms of arthritis development 
between these two models. Many inflammatory diseases, including Lyme arthritis, are 
complex multifactorial disorders, and microRNA expression as a diagnostic tool could be  
used to quickly identify dysregulated pathways, leading to more personalized treatment. 
 
 
Murine Lyme Arthritis as a Model for Inflammatory and  
Autoimmune Diseases 
 Chronic inflammation and dysregulation of TLR signaling can lead to severe 
inflammatory diseases such as systemic lupus erythematosus [62], rheumatoid arthritis 
[63-65], type 1 diabetes [66], and multiple sclerosis [67]. Autoimmune arthritis can also 
be driven by pathogenic gut microbiota [68]. There is increasing consensus in the field of 
autoimmunity that priming the immune response is a necessary stage in autoimmune 
development [5]. Also, as mentioned earlier, type I IFN is associated with several 
autoimmune diseases, such as lupus [16] and more recently, type 1 diabetes [21]. These 
autoimmune diseases all share similarities, in that there appears to be an innate immune 
trigger that sets the stage for clinical disease. Lyme arthritis is unique in that the trigger is 
a known pathogen [1] that is the causative agent of disease pathogenesis, thus fulfilling 
Koch’s postulates [69]. Furthermore, mice are natural hosts of B. burgdorferi, which 
allows for study of host-pathogen interaction and disease progression within a natural 
environment.  
 Functional studies on the role of microRNAs in inflammatory diseases provide 
unique opportunities to examine the role of essential pathways in disease progression or 
resistance, where the “fine tuning” effect rendered by microRNAs can be used to model 
many complex diseases. Elucidating the role of TLR signaling in Lyme arthritis is a 
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perfect example. TLR2 and MyD88 knockout mice had severe defects in signaling which 
led to severely impaired host defense due to their essential role in immune response to 
pathogens [29,31]. While these findings shed valuable light on the necessity of TLR2 in 
host defense, the inability to decouple host defense and inflammation using these 
knockout systems made identifying the role of TLR signaling in arthritis development 
difficult. This difficulty was overcome using the B6 miR-146a-/- mouse model, which 
maintained a functional (albeit hyperactive) TLR signaling pathway, and therefore had no 
defect in host defense.  
Many individuals contain polymorphisms in genes that render proteins (or 
microRNAs) slightly more or slightly less active, without ablating the protein’s (or 
miR’s) function completely, which is often lethal. These individuals may be at risk for 
developing certain diseases, if they are exposed to environmental triggers, such as a viral 
or bacterial infection. Individuals containing hypermorphic alleles of genes involved in 
NF-κB activation (or hypomorphic alleles of genes involved in NF-κB repression) would 
be expected to be phenotypically similar to the B6 miR-146a-/- mouse. Indeed, one study 
discussed previously has shown that individuals containing a certain polymorphism in 
TLR1 are susceptible to treatment-refractory Lyme arthritis [70]. These individuals have 
a cytokine expression profile that is in many ways similar to the profile seen in B6 miR-
146a-/- mice. Another study showed that individuals who had low antibody titers after 
vaccination with OspA (a B. burgdorferi lipoprotein) also had low expression of TLR1 
on the surface of macrophages [71]. Additionally, several studies have shown that 
polymorphisms in miR-146a targets IRAK1 [72,73], TRAF6 [74,75], miR-146a [76], and 
the miR-146a target sequence within the 3’ UTR of IRAK1 [77] are associated with 
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susceptibility to rheumatic diseases. Since susceptibility to these diseases appears to share 
this common pathway, it is reasonable to suppose that B6 miR-146a-/- mice would also be 
more susceptible to models of these diseases as well. This is, in fact, the case. For 
example, in addition to developing more severe Lyme arthritis, B6 miR-146a-/- mice also 
develop more severe ankle swelling in the K/BxN serum transfer model of rheumatoid 
arthritis (Appendix C), and exogenous addition of miR-146a partially ameliorated 
arthritis symptoms in the collagen-induced arthritis mouse model [78]. Thus we see that 
microRNA knockout mice may be used as powerful tools for studying the mechanism of  
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ROLE OF MICRORNA-155 REGULATION BY IL-10 DURING INNATE AND 
ADAPTIVE IMMUNE RESPONSE TO BORRELIA BURGDORFERI  
AND LYME ARTHRITIS DEVELOPMENT 
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Figure A.1. Generation of B6 IL10-/- miR-155-/- double knockout mouse. B6 IL10-/- 
and B6 miR-155-/- mice (generously provided by Dr. Ryan O’Connell) were mated to 
create a IL10-/- miR-155-/- double knockout (DKO) on the B6 background. Shown is an 
agarose gel loaded with PCR product using primers specific for wild-type (WT) and 
knockout (KO) copies of miR-155/Bic (top) and Il10 (bottom), with predicted product 
size indicated on left. First two lanes are from IL10-/- or miR-155-/- single knockout mice 
as controls. Third and last lanes are from the founder DKO female and male, 
respectively. Other lanes (4-8) are from litter of DKO founders. 
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Figure A.2. Effect of mR-155 on arthritis, host defense, and IFNγ response following 
a 4-week infection with B. burgdorferi. (A) Rear ankles were measured in a blinded 
fashion before and after 4 weeks postinfection, and change in ankle measurement is 
shown for B6, miR-155-/-, IL10-/-, and IL10-/- miR-155-/- DKO mice bacterial burden (B) 
and IFNγ profile (C, represented by Ifng and Cxcl10) in joint tissue was assessed by qRT-
PCR analysis of B. burgdorferi 16SrRNA in joints, normalized to βactin. (D) Serum 
levels of IFNγ and IL-12 were measured by ELISA in the 4 strains indicated. Statistical 
significant difference between groups was determined by ANOVA followed by Tukey’s 
post-hoc analysis (* p<0.05, n ≥ 7 mice per group). 
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Figure A.3. Antibody response to B. burgdorferi is negatively regulated by IL-10 and 
positively regulated by miR-155 at 4 weeks postinfection, and miR-155 is required 
for IgG1 isotype switching. B. burgdorferi-specific antibody levels were measured by 
ELISA in 2-fold serial dilutions in sera collected from B6 (black circles), B6 miR-155-/- 
(blue squares), B6 IL10-/- (pink triangles), and DKO (gray diamonds) mice infected for 4 
weeks. Total IgG, IgM, IgG1, IgG2c, and IgG3 were measured (n=≥7 mice per strain).  
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Figure A.4. Macrophage B. burgdorferi-induced cytokine production and IFNγ 
profile are negatively regulated by IL-10 and positively regulated by miR-155. Bone 
marrow-derived macrophages were cultured from B6, B6 miR-155-/-, B6 IL10-/-, and 
DKO mice, and were stimulated with B. burgdorferi for 24 hours (MOI 10:1). (A) 
Supernatant was collected and IL-10, IL-1β, IL-6, and IL-12 cytokine levels were 
measured by ELISA. (B) RNA was extracted from cells and transcripts quantified by 
qRT-PCR. Shown are transcripts levels of miR-155, Tnfa, Cxcl9, and Cxcl10. Statistical 
significant difference between groups was determined by ANOVA followed by Tukey’s 
post-hoc analysis (*p<0.05, n=3 per strain, n.d.=none detected). 
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Figure A.5. B cells from draining lymph nodes are major producers of IFNγ when 
stimulated with B. burgdorferi, which is independent of IL-10 and miR-155. Inguinal 
and popliteal lymph nodes were collected from B6, B6 miR-155-/-, B6 IL10-/-, and DKO 
mice and cells were stimulated with B. burgorferi in vitro (MOI 10:1). At 3 and 5 days 
poststimulation, cytokine production was measured in cells by intracellular cytokine 
staining followed by flow cytometry. Shown is mean fluorescence intensity for IFNγ and 
TNFα in B220+ cells (n=3 per group). 
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EFFECT OF IL-10 ON T AND B CELL PROLIFERATION IN LYMPH NODES,  
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Figure B.1. B6 IL10-/- mice contain greater numbers of B and T cells in draining 
lymph nodes than wild-type B6 mice after infection with B. burgdorferi for 4 weeks. 
Inguinal and popliteal lymph nodes were collected from B6 and B6 IL10-/- mice infected 
with B. burgdorferi for 4 weeks and analyzed by FACS. (A) Representative FACS plot of 
CD4+ T cells labeled with T cell activation markers CD44 (y-axis) and CD62L (x-axis). 
Top row are cells from uninfected B6 and IL10-/- mice, and bottom row are cells from B6 
and IL10-/- mice infected for 4 weeks. (B) Total cells collected from uninfected and 
infected B6 and IL10-/- lymph nodes, categorized by B220+ (B cells), B220+ CD62Llo 
(activated B cells), CD4+ T cells, CD4+ CD62Llo CD44hi (activated CD4+ T cells), and 
CD8+ T cells. Statistical significant difference between groups was determined by 
ANOVA followed by Tukey’s post-hoc analysis (*p<0.05, n=3 mice for each group, 
representative of 2 independent experiments). 
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Figure B.2. Effect of antibiotic treatment on arthritis severity, IFNγ profile, and T 
cell activation in B6 IL10-/- mice. (A) B6 IL10-/- mice were infected with B. burgdorferi 
for 3 weeks followed by daily administration of ceftriaxone (or PBS) by i.p. injection for 
4 weeks. Mice were assessed for arthritis, Ifng expression, and T cell activation at 9 
weeks postinfection. (B) Arthritis was assessed by ankle measurement. Ifng expression 
was measured by qRT-PCR in joint, back skin (site of inoculation), and ankle skin in 
mice with or without ceftriaxone treatment at 3 and 9 weeks postinfection (+ BSK 
negative controls). Statistical significant difference between groups was determined by 
ANOVA followed by Tukey’s post-hoc analysis (*p<0.05, ***p<0.001, n≥5 mice per 
group). (C) Representative FACS plot of CD4+ (top) and CD8+ (bottom) T cells labeled 
with T cell activation markers CD44 (y-axis) and CD62L (x-axis) from uninfected, 
infected (no antibiotic treatment), and infected + antibiotic treated mouse inguinal and 
popliteal lymph nodes collected at 9 weeks postinfection. Representative of at least 5 
mice per group. 
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Figure C.1. B6 miR-146a-/- mice have increased K/BxN serum-induced arthritis. B6 
and B6 miR-146a-/- mice were administered 2 doses (day 0 and day 2) of 100 µl K/BxN 
serum by i.p. injection. Ankle swelling and histopathology scoring was determined at day 
7 following administration of first dose. Statistical significant difference in ankle swelling 
was determined by ANOVA followed by Tukey’s post-hoc analysis (*p<0.05, n=10 mice 
per group). Increased trend in histopathology score was not statistically significant 
between groups by Mann-Whitney u-test (cutoff p value=0.05).  	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